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ABSTRACT 
This thesis investigated the role of xenobiotic and endogenous quinones in modulating 
major intracellular protein handling systems including the 20/26S proteasome, autophagy, 
the ER stress response, heat shock proteins (HSPs) and aggresome formation.  
The activation sequence of diverse protein handling systems was first defined using 
the proteasome inhibitor MG132 in rat dopaminergic N27 cells. The data suggested that 
after proteasomal inhibition, the ER stress response was most rapidly triggered and 
subsequent induction of autophagy and Hsp70 expression was important for protection 
against accumulation of intracellular protein aggregates. Three model quinones including 
the environmentally relevant 1,4-benzoquinone (BQ), the vitamin K analog menadione 
(MD) and aminochrome (AC) a reactive dopamine oxidation product, were utilized to 
determine quinone-induced protein handling changes in N27 cells. The results 
demonstrated that the nature and extent of protein handling changes were quinone-specific. 
BQ and AC could inhibit proteasomal activity and trigger a rapid activation of the ER 
stress response and autophagy in N27 cells. AC induced aggresome formation and caused 
the most pronounced protein handling changes, while MD had little effect on any protein 
handling system. The effect of NAD(P)H:quinone oxidoreductase 1 (NQO1) was also 
quinone-dependent. NQO1 inhibited the ER stress response and protected against BQ 
toxicity but potentiated both the ER stress response and toxicity of AC and MD.  
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      Finally, the ability of 19-substituted benzoquinone ansamycins (19BQAs) novel 
antitumor Hsp90 inhibitors, to modulate protein handling systems was defined using 
human dopaminergic SH-SY5Y (5Y) cells. The results demonstrated that 19BQAs had 
decreased toxicity in 5Y cells relative to their parent quinones geldanamycin (GA), 17-
AAG and 17-DMAG while retaining the ability to induce HSP expression and autophagy. 
Whether 19BQAs could protect against protein aggregation and toxicity was further 
examined using an A53T α-synuclein Parkinson’s disease (PD) cellular model. 19-Phenyl-
GA (19-Ph-GA), a lead compound in the GA series significantly decreased the oligomer 
formation and toxicity of A53T α-synuclein in 5Y cells. Mechanistic studies demonstrated 
that 19-Ph-GA activated Hsp70, Hsp27 and autophagy and attenuated mTOR activation in 
A53T α-Syn overexpressing cells, all of which might contribute to protection against 
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REVIEW OF THE LITERATURE AND STATEMENT OF PURPOSE 
General mechanism of quinone toxicity 
      Quinones are a ubiquitous class of naturally occurring compounds and over 1,500 
quinones have been found in plants, fungi and bacteria as well as throughout the animal 
kingdom (1, 2). Quinones also exist as endogenous biochemicals that can be generated 
through oxidative metabolism of catecholamines and estrogens in humans (3). Many 
chemotherapeutic agents including anthracyclines, streptonigrin, mitomycins, 
naphthoquinones and benzoquinone ansamycins all contain the quinone nucleus 
suggesting it is an important pharmacophore in medicinal chemistry (4-7). Because 
human exposure to quinones can occur via the diet or via airborne pollutants, a 
substantial amount of work has focused on elucidating the biochemistry and toxicology 
of quinones (8). 
      Quinones can undergo non-enzymatic and one-electron enzymatic (i.e., NADPH-
cytochrome P450 reductase or NADH-cytochrome b5 reductase) reduction to 
semiquinone radicals (Fig. 1.1). Semiquinones are able to disproportionate with another 
molecule of semiquinone to form one molecule of quinone and one molecule of 
hydroquinone. Alternatively, in the presence of oxygen, the semiquinone can also 
undergo oxidation to generate superoxide anion radical and regenerate the quinone which 
is then available for repeated reduction a process termed redox cycling (9, 10). The 
ability of semiquinones to react with molecular oxygen is controlled by their redox 
potential (8, 11). The redox cycling of quinones can lead to the formation of reactive 
oxygen species (ROS) including superoxide anion radicals, hydrogen peroxide and 
hydroxyl radicals (8). Generation of ROS can catalyze oxidation of essential cellular 
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macromolecules causing severe oxidative stress and toxicity. For example, oxidation of 
cysteine residues in proteins can dramatically alter protein structure and function. 
Hydroxyl radicals catalyze oxidation of lipids, generating lipid hydroperoxides and cause 
the formation of lipid peroxide-derived malondialdehyde DNA adducts (12-17).  
      Quinones are also electrophiles. Cellular damage due to these species can result from 
reaction with nucleophilic amino groups on proteins or DNA, or covalent binding with 
cellular thiols, such as GSH or cysteine residues on proteins, leading to depletion of 
cellular GSH levels and/or protein arylation (Fig. 1.1). Previous studies have identified 
many arylation targets of quinones including tubulin, histone, topoisomerase II, Keap-1, 
protein tyrosine phosphatases (3, 18-21). Adducts to any of these critical proteins can 
cause cellular toxicity by either impairing protein function or disrupting related 
regulatory pathways. For example, menadione can stimulate the tyrosine kinase receptor 
and activate the MAPK/ERK pathway that can in turn induce loss of gap junction 
intercellular communication in cells and toxicity (22-24). Quinone-protein adducts such 
as acetaminophen protein conjugates have also been found to induce indirect immune 
responses and lead to toxicity (25). 
     While one-electron reduction of quinones results in semiquinone radicals, two-
electron enzymatic reduction by NAD(P)H: quinone oxidoreductase 1 (NQO1) or NRH: 
quinone oxidoreductase 2 (NQO2) generates hydroquinones which are substrates of 
Phase II conjugation reactions for further excretion (Fig. 1.1). However, the conjugation 
of quinones to sulfhydryls such as glutathione (GSH) does not necessarily result in 
detoxification, even when the phenolic GSH-conjugates are stable to oxidation (18, 26). 
In fact, the accumulation of phenolic GSH-conjugates has been found to contribute to 
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multiple organ and tissue toxicities, particularly in cells that express high levels of γ-
glutamyl transpeptidase (γ-GT) or exhibit high activity of intact GSH importers (27). 
Moreover, a single molecule of a quinone can also undergo multiple nucleophilic 




































Figure 1.1 Schematic representation of quinone toxicity through oxidative stress and 
arylation. 
      Importantly, the toxicology of quinones is also determined by their relative 
electrophilicity and redox potential that can be strongly influenced by the substituents. 
For example, addition of an electron donating substituent such as hydroxyl or methoxy to 
a quinone leads to a weaker oxidant and its reduced or hydroquinone forms are more 
easily oxidized. Conversely, addition of an electronegative group (e.g. nitro-, halogen- 
and carbonyl) to a quinone results in a stronger oxidant and the hydroquinone forms are 
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less easily oxidized (18). In conclusion, a variety of adverse effects including 
immunotoxicity, nephrotoxicity, hematotoxicity, neurotoxicity and carcinogenesis 
mediated by many quinones can be attributed to the reactive oxidant and electrophilic 
properties of quinones.  
Major protein handling systems and the capability of quinones to modulate protein 
handling activities in cells 
      Protein handling systems including the ubiquitin-proteasome system (UPS), 
autophagy, the ER stress response/unfolded protein response (UPR), heat shock proteins 
(HSPs) and aggresome formation are critical for maintaining proteome homeostasis in 
cells (29-33). Although the mechanism of quinone toxicity has been intensively 
investigated, few studies have systematically examined the effects of quinones on protein 
handling systems and its relationship to quinone toxicity. Recently, several quinones, 
including the dopamine oxidation product aminochrome, the benzene reactive metabolite 
1,4-benzoquinone and the vitamin K analog menadione have been shown to induce 
protein handling changes in cells (14, 21, 34, 35). This previous work implied a role of 
proteolytic stress in the effects of quinones in cellular systems although the specific 
effects on protein handling, interestingly, between protein handling systems and 
ultimately the contribution of changes in protein handling systems to toxicity were 
unclear. 
The ubiquitin-proteasome system (UPS) 
     Ubiquitin is a highly conserved and abundant protein in cells, and it was first 
described and named in 1975 (36). From 1978-1985, ubiquitin was identified in rabbit 
reticulocytes extract as an essential component of the ATP-dependent proteolytic system, 
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termed as the 26S proteasome (37-39). The ubiquitin-proteasome system (UPS) is the 
major degradation system in the cytosol and nucleus of all eukaryotic cells. Most 
substrates of the UPS are short lived, damaged and misfolded proteins and are labeled for 
degradation by attachment of multiple ubiquitin molecules. The resulting ubiquitinated 
proteins are then recognized and degraded by the 26S proteasome (Fig. 1.2) (40, 41). 
More specifically, three distinct classes of ubiquitin binding enzymes including ubiquitin 
activating enzyme (E1), ubiquitin conjugating enzyme (E2) and ubiquitin-ligase (E3) 
catalyze binding of ubiquitin to a lysine (K) residue in the substrate protein. Additional 
ubiquitin molecules can then be added to the attached ubiquitin molecule by ligating onto 
one of seven lysine residues (K6, K11, K27, K29, K33, K48 and K63). 
Polyubiquitination on K48 and K63 is specifically targeted to degradation pathways 
while other ubiquitin chains participate in different processes such as cellular signal 
transduction (42, 43). Humans contain 2 E1 (44) and approximately 40 E2 and 600 E3 
enzymes (45). E3 enzyme is highly substrate specific and responsible for selecting client 
proteins to the UPS.  
     The 26S proteasome is a ~2000kDa ATP-dependent, multifunctional proteolytic 
complex that consists of a 20S proteasome proteolytic core and two 19S regulatory 
complexes. The 19S regulatory complex is formed by a lip and base that functions to 
recognize substrate proteins and facilitate their degradation by the 20S proteasome (46). 
Free intracellular 20S proteasomes are normally found in an inactive state and require the 
binding of 20S activators such as the PA28 complex or the Blm10/PA200 protein to 
degrade proteins (47). The 20S proteasome core is composed of four rings that contain 
heteromeric α subunits (outer rings) and β subunits (inner rings). Six β subunits on the 
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20S proteasome are catalytically active: two β5 subunits termed “chymotrypsin-like” cut 
preferably after hydrophobic residues, two β1 subunits named “caspase-like” cleave after 
aspartic acid residues and other two β2 subunits sites are “trypsin-like” and cleave 
preferentially after basic amino acids (48). Although the chymotrypsin-like site 
contributes most to the catalytic activity of the proteasome, the activities of other 
peptidase sites can be allosterically stimulated or inhibited by peptide substrates and 
small molecules acting on non-catalytic regulatory sites (49-51). Unlike other proteases, 
all the proteolytic sites in the 20S proteasome utilize N-terminal threonines as the active 
nucleophiles (48).  
      The 20/26S proteasome is responsible for degradation of the majority of intracellular 
proteins that participate in cell-cycle regulation, DNA repair, cell growth and immune 
function. For example, the proteasomal degradation of the tumor suppressor p53 
contributes to oncogenesis (52), and the proteasomal degradation of IκB activates the 
transcription factor NF-κB that in turn triggers inflammatory responses (53, 54). With 
increased knowledge about the critical role of the proteasome in mammalian cells, 
proteasome inhibitors have attracted interest over the years particularly with respect to 
their utilization in cancer therapy (55). The first proteasome inhibitor Bortezomib was 
approved by the U.S. Food and Drug Administration on May 2003 for the treatment of 
multiple myeloma (56).  
       Since the proteasome exists abundantly in cytosol and is rich in cysteine and lysine 
residues (57), it is potentially a good target of arylating quinones. Indeed, previous 
studies have demonstrated that dopamine oxidation products including cyclized quinones 
were capable of inhibition of proteasomal activity in rabbit reticulocyte lysates (12, 58).  
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Figure 1.2 The ubiquitin proteasome system (UPS). Protein degradation by the UPS is 
mediated by the attachment of polyubiquitin chain through an enzymatic sequential 
mechanism involving E1, E2 and E3 ligases. The polyubiquitylated protein can be 
recognized and degraded by the proteasome that in turn leads to cleavage of small 
peptides. The proteasome is involved in a variety of cellular functions and signaling 
pathways, such as protein quality control, stress response or cell cycle regulation. The 
figure is reprinted by permission from Macmillan publishers Ltd: Nat Commun (47), 
©2014. 
More recently, thymoquinone a substituted benzoquinone analog has been shown to 
induce proteasomal inhibition and apoptosis in glioblastoma cells (59). However, these 
studies did not discriminate the role of redox cycling and arylation in quinone-mediated 
proteasomal inhibition, and did not examine any compensatory changes in other protein 
handling systems after proteasomal inhibition.  
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Autophagy 
      Along with the UPS, autophagy is another major intracellular degradation pathway in 
eukaryotic cells and is responsible for the degradation of long lived, aggregate-prone 
proteins and damaged organelles (60). After the discovery of the lysosome system in 
1955, autophagy was first described in 1962 by transmission electron microscopy (TEM) 
(61, 62). TEM studies showed that the double-membrane vesicles contained lysosome, 
mitochondria and fractions of cytoplasm, and this self-eating process were named as 
autophagy (62-64). There are three major forms of autophagy: microautophagy, 
chaperone mediated autophagy (CMA) and macroautophagy. The different forms are 
characterized by how substrates are delivered to the lysosome for degradation. 
Microautophagy involves the direct engulfment of substrates and surrounding cytosolic 
content to the lysosomal membrane (65). CMA targeted substrate protein is first 
recognized by a specific motif in heat-shock cognate 70 (Hsc70) and lysosomal 
membrane protein Lamp2A (Lamp2A) and then transported into the lysosome for 
degradation (66). Macroautophagy requires the formation of a double-membrane vesicle, 
the autophagosome, which directly engulfs the target cytosolic content and subsequently 
fuses with the lysosome for degradation (67). This thesis mainly focuses on 
macroautophagy and hereafter refers to it as autophagy. 
      As illustrated in Figure 1.3, autophagy is a highly regulated process that involves at 
least 20 autophagy gene (Atg) related proteins to sequester and degrade the targeted 
cellular materials including damaged organelles, long-lived proteins and toxic aggregates 
(67). The first step of autophagy involves the derepression of the mTOR kinase, which 
suppresses autophagy by phosphorylating Atg13. Inhibition of mTOR results in 
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dephosphorylated Atg13 that can interact and stimulate Atg1 catalytic activity and initiate 
the double-membrane vesicle formation (step 2). The vesicle elongation process (step 3) 
is mediated by the ubiquitin-like conjugation systems with the help of multiple Atg 
proteins. The lipid conjugation of phosphatidylethanolamine (PE) to autophagy related 
microtubule-associated  protein  1 light chain 3 (LC3 / Atg8)  leads to  the  conversion  of  
the  soluble  form  of  LC3  (LC3 I)  to  LC3 II,  the  autophagy  vesicle-associated  form. 
 
Figure 1.3 Autophagy degradation. Autophagy involves at least 20 Atg related proteins to 
sequester the targeted cellular materials (damaged organelles, long-lived proteins and 
toxic aggregates) into a vesicle termed a double-membrane autophagosome which 
subsequently fuses with lysosome for degradation. The figure is reprinted by permission 
from Macmillan publishers Ltd: Nat. Rev. Mol. Cell Biol. (67), ©2007. 
Because of the specific involvement of LC3 II to autophagosomes, it is therefore used as 
a marker of autophagy. Autophagosomes can further fuse with lysosomes to generate 
autolysosomes (steps 5 and 6). Lysosomal enzymes then degrade the content and the 
inner membrane of autophagosomes to complete the autophagic degradation process. 
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Pharmacological inhibitors such as chloroquine that can block the fusion of 
autophagosomes with lysosomes and inhibit the autophagy degradation process are useful 
tools to study chemical- or stress-induced autophagy. 
      Autophagy occurs at a basal level but can also be activated by nutrient deprivation or 
other types of cell stresses. Inactivation of basal autophagy has been shown to induce 
formation of cytoplasmic protein inclusions and lead to liver injury and 
neurodegeneration (68, 69). A crosstalk between the UPS and autophagy has been 
suggested as both of them are involved in degradation of ubiquitinated proteins. Under 
physiological conditions, the UPS prefers to degrade K48 ubiquitinated proteins while 
autophagy only targets K63 ubiquitinated proteins. However, under stress conditions (e.g. 
stimuli of the ER stress and impaired proteasome function), autophagy can degrade the 
substrates of the UPS (30). The poly-ubiquitin binding protein p62/SQSTM1 (p62), 
another commonly used autophagy marker, has been shown to function as a bridging 
factor between the UPS and autophagy (70, 71). Although p62 prefers to bind K63 
ubiquitinated proteins for autophagy degradation, it can also bind K48 ubiquitinated 
proteins when they are not effectively cleared by the UPS and divert them to autophagy. 
Previous studies have demonstrated that inhibition of proteasome activates autophagy and 
the toxicity mediated by proteasomal inhibition can be ameliorated by up-regulation of 
autophagy (72, 73). Because dysfunction of autophagy has not been demonstrated to 
modulate proteasome activity, autophagy is generally recognized as a compensatory 
degradation system to the UPS (30).              
      The dopamine derived ortho-quinone AC has been shown to inhibit proteasomal 
activity in cell free systems and induce autophagosome formation in neural cells (16). 
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Since AC has been proposed as a contributing factor to aberrant protein folding and the 
etiology of Parkinson’s disease (19), it is important to understand the capability of AC to 
modulate protein handling systems and any potential relationship to neurotoxicity.  
The Endoplasmic Reticulum (ER) stress response/Unfolded Protein Response (UPR) 
       The ER is a crucial compartment for synthesis, folding and quality control of most 
secretory and transmembrane proteins (74). Three sensors at the ER membrane: inositol 
requiring enzyme 1 (IRE1), activating transcription factor 6 (ATF6) and the PKR-like ER 
kinase (PERK) can be activated to enhance the folding capacity as well as cell defense 
against stress in the ER (Fig. 1.4) (75). When challenged with unfolded/misfolded 
proteins, the ER stress sensor PERK is most rapidly activated by autophosphorylation. 
Following activation, PERK phosphorylates eIF2α to inhibit protein translation and 
alleviate the burden of newly synthesized polypeptides to stressed cells (76). EIF2α 
phosphorylation can further activate ATF4 to enhance the expression of cytoprotective 
genes. ER stress also triggers the transition and cleavage of ATF6 in Golgi complex as 
well as the activation of IRE1 to initiate the splicing of XBP-1 mRNA and generate an 
active transcription factor sXBP-1 (77). The activation of IRE1 signaling and the 
cleavage of ATF6 upregulate the ER–localized chaperones expression and promote the 
expansion of ER for cell survival (78). However, if the stress is too severe and these 
adaptive responses are not sufficient to handle the unfolded/misfolded proteins in the ER, 
C/EBP homologous protein (CHOP) and caspase 12 are activated to induce the ER stress 
associated apoptosis (79, 80). Notably, unfolded/misfolded proteins arise in the ER and 
can be exported to the cytosol and degraded by the UPS, a process called ER associated 
degradation (ERAD) (81). Several lines of evidence suggest a link between the UPR, 
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UPS and autophagy. Under conditions of proteasomal inhibition, PERK/eIF2α signaling 
has been shown to most effectively respond and activate autophagy in both cancer and 
neural cells (82-86). Interestingly, other stressors such as oxidative stress or nutrient 
deprivation also activate eIF2α phosphorylation and induce autophagy as a protective 
response, suggesting that phosphorylated eIF2α may act as a bridging factor between the 
UPR and other signaling pathways (30, 87).  
 
Figure 1.4 The ER stress response/UPR. Accumulation of unfolded/misfolded proteins in 
the ER triggers the UPR, which consist of three signaling pathways that respectively 
mediated by PERK, ATF6 and IRE1. The figure is reprinted by permission from 
Macmillan publishers Ltd: Nat Neurosci (79), ©2009.  
 
      Arylating quinones including BQ have been shown to induce ER stress and activate 
the PERK/elF2α signaling pathway in neural cells (14). However, whether quinone 
mediated changes in the ER stress response are associated with the changes in other 
protein handling systems such as the UPS and autophagy remains unclear. 
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Heat Shock Proteins (HSPs) 
      To maintain proteome homeostasis, cells have developed compartment-specific stress 
responses to detect and restore unfolded and misfolded protein. The UPR is specific for 
guiding protein refolding in the ER, while the heat shock protein response is activated for 
quality control of cytoplasmic proteins and enables cells from animals, plants and 
bacteria to survive environmental stresses (88). One major family of molecular 
chaperones is the heat shock proteins (HSPs). The synthesis of HSPs is mediated by heat 
shock transcription factor 1 (HSF-1). It has been shown that genetically or 
pharmacologically enhancing the activity of HSF-1 can increase the concentrations of 
HSPs and restore protein homeostasis in several models of diseases (88, 89). HSPs are 
generally a protective mechanism against unfolded/misfolded proteins, but there is 
evidence indicating that the HSP response is not induced effectively in neurodegenerative 
diseases including Huntington’s disease and Parkinson’s disease, even when damaged 
proteins are accumulated (90, 91). Elevated expression of HSF-1 and HSPs have been 
implicated in human cancers (92) such as breast cancer and prostate cancer. It has also 
been demonstrated that increased Hsp70 expression contributes to tumorgenesis through 
inhibition of apoptosis (93, 94). More recently, HSF-1 has been proposed as a prognostic 
marker for hepatocellular carcinoma (95). 
      HSPs are classified into six families on the basis of their approximate molecular mass 
(Table. 1.1): Hsp100, Hsp90, Hsp70, Hsp60, Hsp40 and the small HSPs (20 to 25 kDa) 
(96-99). Increasing number of diseases have been associated with impaired functions of 
these molecular chaperones (100, 101).  
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Table 1.1. Families of HSPs 
HSP Family                     Major functions                                             Size/Species 
Hsp100              Protein disaggregation, thermotolerance                   104 kDa in yeast  
                                                                                                              No mammalian homologue 
Hsp90                Stabilization of misfolded proteins                            90 kDa in mammals 
                           Regulation of the activity of signaling proteins         83 kDa in Drosophila and bacteria 
                           More than 200 Hsp90 client proteins  
Hsp70                Protein folding and disaggregation                           72 and 73 kDa in mammals 
                           Membrane transport of proteins                               70 and 68 kDa in Drosophila 
                           Hsp70 Family members include                               70 kDa dnaK proteins in Escherichia coli                                             
                           the heat shock cognate 70 (HSC70),  
                           the stress-induced cytosolic HSP70,  
                           the endoplasmic reticulum-localized  
                           glucose-regulated protein 78 (GRP78),  
                           and the mitochondrial GRP75  
Hsp60                Protein folding                                                           56/58 kDa in eukaryotic mitochondrial proteins  
                           (Limited substrate in eukaryotic cytoplasm)             and the GroEL protein in Escherichia coli                                             
Hsp40                Protein folding                                                           40 kDa in animals, plants  
                           Co-chaperone for Hsp70                                            and Escherichia coli                                            
    Small HSPs      Protein disaggregation                                               20 to 30 kDa in animals 
                              Stabilization of misfolded proteins                            17 to 28 kDa in plants 
                              Degradation of misfolded complexes                                                
                              Thermotolerance and eye lens structural proteins 
 
      Hsp70 and Hsp27 are two of the most thoroughly studied HSPs that have been shown 
to protect against unfolded/misfolded protein toxicity in a variety of neurodegenerative 
disease models (102-106). Interestingly, a link between HSPs and autophagy has recently 
been proposed. Hsp70, as one of the major HSPs activated by the heat shock response, 
was found to affect the integrity and function of the lysosome and modulate the turnover 
of autophagic flux (107). Moreover, pharmacological inhibition of Hsp70 can inhibit 
autophagic clearance and promote aggregate formation (108). Interestingly, arylating 
quinones such as  γ-tocopherol quinone and nathphoquinone have been shown to 
conjugate with intracellular proteins and the resultant quinone protein adducts were 
associated with elevated HSP expression and toxicity in cells (14, 35). 
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Aggresome formation   
      When normal proteins are turned over by protein degradation systems including the 
UPS and autophagy, unfolded/misfolded proteins occurring as a result of cellular stress 
are recognized by molecular chaperones and are either refolded or delivered to 
degradation systems. However, if the protein degradation systems are impaired or the 
altered proteins form oligomers that cannot be recognized by the UPS and overwhelm the 
clearance ability of autophagy, such oligomers are then transported in a microtubule-
dependent manner to the perinuclear microtubule-organizing center (MTOC) (109) to 
form ubiquitin containing protein aggregates known as aggresomes (110) (Fig. 1.5). 
Aggresome formation is usually accompanied by a dramatic reorganization of 
cytoskeleton intermediate filaments including vimentin and γ-tubulin which collapse to 
form a ‘cage’ surrounding the ubiquitin positive aggregates (111). Interestingly, Lewy 
bodies in PD display many similarities to aggresome formation, particularly in the 
composition of ubiquitinated proteins (112, 113). 
      The formation of aggresomes may be an alternative route for the segregation and 
removal of abnormal and potentially toxic proteins. Although the proteinaceous inclusion 
bodies are a pathological feature of many neurodegenerative diseases including 
Parkinson’s, Alzheimer’s and Huntington’s disease (114), the presence of inclusion 
bodies in these disorders has been found to correlate poorly with neurodegeneration 
markers (115-118). While aberrant protein aggregation may be associated with toxicity, 
aggresome formation represents a cellular protective response that can sequester 




Figure 1.5 Major protein handling systems protect against abnormal proteins in cells. 
Unfolded/misfolded proteins can be refolded and disaggregated by molecular chaperones 
such as HSPs, or alternatively, they can be targeted and diverted to the UPS or autophagy 
for degradation. When the accumulation of abnormal proteins exceed the capacity of the 
chaperone and degradation systems, they are transported to the perinuclear region to form 
an aggresome. The figure is reprinted by permission from Macmillan publishers Ltd: Nat. 
Rev. Mol. Cell Biol. (119), ©2005. 
 
      The interrelationship between aggresome and other protein handling systems 
including the UPS and HSPs has been demonstrated. Functional blockade of the UPS 
leads to increased aggresomes (123) and increased expression of HSPs, suggesting that 
the formation of aggresomes is tightly associated with the activity of other protein 
handling systems (124-127). Both AC and BQ have been shown to disrupt the 
microtubule network by conjugating with thiol groups of tublin and in turn induce 
toxicity in cells (17, 128, 129). This evidence suggests that quinones have the capability 
to inhibit aggresome formation by perturbing the microtubule network. 
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Implications of AC induced protein handling changes in the pathogenesis of 
Parkinson’s disease 
      Parkinson’s disease (PD) is one of the common progressive neurodegenerative 
diseases that is characterized by selective loss of dopaminergic neurons in the substantia 
nigra pars compacta and presence of intracytoplasmic proteinaceous inclusions known as 
Lewy bodies (130). Although the molecular mechanisms of loss of dopaminergic neurons 
are not fully understood, dysfunction of protein degradation systems such as the 
proteasome has been proposed as one of the factors in the pathogenesis of both familial 
and sporadic PD (29, 131-133). Previous studies have characterized changes in 
downstream protein handling secondary to proteasomal inhibition and these include up-
regulation of HSPs, induction of molecular chaperones, activation of the UPR, autophagy 
and aggresome formation (112, 134).  
      Since the incidence of PD increases rapidly after the fifth decade and affects ~2% of 
individuals over the age of 65 (135), PD is generally recognized as an aging disorder. 
During the aging process, dopamine can be oxidized and generate highly reactive 
ortho(o)-quinone species that have been proposed as contributing factors to PD (136-
138). Dopamine o-quinones, AC and 5,6-indolequinone are three of the most reactive 
quinone species found during dopamine oxidation (19). As shown in Figure 1.6, 
dopamine can be oxidized spontaneously to o-semiquinone or o-quinone and generate 
superoxide anion radical in the presence of oxygen. Catalytic ions including copper (II) 
(139), iron (III) (140, 141) and manganese (III) (142) are also capable of catalyzing 
dopamine oxidation under both aerobic and anaerobic conditions. Enzymatically, 
prostaglandin H synthase, cytochrome P450, xanthine oxidase and lactoperoxidase have 
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been shown to be involved in the oxidation of dopamine and subsequent ROS formation 
(143-147). Unlike these enzymes, tyrosinase can catalyze the two-electron oxidation of 
dopamine to o-quinone without generating semiquinone (148). Since dopamine o-
quinone is unstable at physiological pH, it spontaneously undergoes cyclization and 
oxidation to AC which further rearranges to 5,6-didydroxyindole and polymerizes to 


















































Figure 1.6 The oxidation pathways of dopamine to AC. Dopamine oxidation products 
include three major quinone species: dopamine o-quinone, AC and 5,6-indolequinone. 
AC is a relatively more reactive neurotoxin that has been used as a model neurotoxin to 
study PD.  
 
A number of studies have reported that dopamine oxidized quinones could conjugate 
with a variety of proteins including parkin (152), tyrosine hydroxylase (153), dopamine 
transporter (154), quinoprotein adducts (155), mitochondrial glutathione peroxidase 4 
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(156), mitochondrial complex, isocitrate dehydrogenase, superoxide dismutase 2 (157) 
and tryptophan hydroxylase (158). The question arises as to which quinone species is the 
most relevant for the formation of protein adducts. Results from spectroscopy studies 
suggest that dopamine o-quinone and 5,6-indolequinone are not only rapidly detoxified 
by GSH (159, 160) but also less stable than AC under physiological conditions (149, 159, 
161, 162). At physiological pH, only AC (470nm) but not dopamine o-quinone (390nm) 
is detectable during the tyrosinase mediated oxidation of dopamine (163). Moreover, it 
has been shown that dopamine o-quinone undergoes rapid cyclization to AC with a 
reaction rate constant of ~0.15s
-1
, while AC rearranges to generate 5,6-indolequinone 
with a rate constant of ~0.06min
-1
 suggesting that the formation of 5,6-indolequinone is 
markedly slower resulting in accumulation of AC (159, 161). These data suggest that AC 
would be the predominant dopamine oxidation product in dopaminergic cells. In addition, 
the presence of neuromelanin in the dopaminergic neurons of PD substantia nigra also 
supports the occurrence of dopamine oxidation to AC in vivo as AC is a precursor of 
neuromelanin (164). Despite the fact that free cytosolic dopamine is transported and 
metabolized by both vesicular monoaminergic transporter-2 (VMAT-2) (165) and 
monoamine oxidase (MAO) (166), the presence of neuromelanin suggests that these 
enzymes do not entirely limit dopamine flux through the AC pathway. 
      AC induces mitochondrial dysfunction, formation of neurotoxic protofibrils of α–
synuclein as well as impairment of protein degradation, and it has been used as a model 
neurotoxin to study PD in both cell and animal models (19, 128, 136-138, 143, 167, 168). 
The mechanism of AC induced neurotoxicity is suggested to occur via one-electron redox 
cycling leading to oxidative stress and/or arylation with cellular nucleophiles including 
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GSH (169) and neuronal proteins (170-172) (Fig. 1.7). Recently, AC has been shown to 
exert an inhibitory effect on proteasomal activity and activate autophagy in dopaminergic 




































Figure 1.7 The mechanisms of AC induced neurotoxicity. 
The role of NQO1 in quinone mediated toxicity 
      NAD(P)H: Quinone oxidoreductase 1  (NQO1), also known as DT-diaphorase was 
discovered in 1958 (173-175). NQO1 is the only flavoenzyme that contains two flavin 
adenine dinucleotide (FAD) molecules and catalyzes the two-electron reduction of 
quinones using NAD(P)H as electron donator (176). Because the substrate binding site of 
NQO1 is flexible, this enzyme can accommodate and metabolize a variety of quinones 
(176, 177).  
      NQO1 can protect against the electrophilic properties of quinones by reduction of the 
quinone to hydroquinone and is also considered to be an antioxidant enzyme, because it 
catalyzes the two-electron reduction of quinones to less reactive hydroquinones and 
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bypasses the one-electron reduction to semiquinones and subsequent ROS formation 
(178). A series of studies have shown that NQO1 can protect against quinones including 
BQ and MD toxicity in both cells and animal models (16, 179-183). Studies 
compromising the expression of NQO1 pharmacologically or genetically indicated that 
NQO1 is a susceptibility factor for AC neurotoxicity (16, 34, 168, 184-188). Besides 
xenobiotic quinones, NQO1 also catalyzes the two-electron reduction of endogenous 
quinones such as vitamin E (α-tocopherol) and ubiquinone (coenzyme Q10) to generate 
the antioxidant forms of these molecules and protect cells from free radical attack and 
lipid peroxidation (189, 190). Moreover, NQO1 can directly scavenge superoxide by 
functioning as a superoxide reductase in cells (191) and it is highly inducible by various 
electrophiles under regulation of the Keap1/Nrf2/ARE and AhR receptor/XRE pathway 
(192-194). The antioxidant role of NQO1 is further supported by human 
immunohistochemical studies that have shown NQO1 is highly expressed in many tissues 
requiring high levels of antioxidant protection (195, 196). In addition, dopaminergic 
neurons in the PD substantia nigra have increased NQO1 expression suggesting that 
induction of this enzyme may act as a protective stress response (197). Indeed, 
overexpression of NQO1 in human SK-N-MC neuroblastoma cells has been shown to 
protect against dopamine induced toxicity (198). In addition to the role of NQO1 in the 
detoxification of various xenobiotic and endogenous quinones (199-201), this enzyme 
has also been shown to function as a gatekeeper of the 20S proteasome (202-204). Recent 
studies reported that NQO1 can bind and stabilize p53 and other tumor suppressor 
proteins such as p73, p33, p63 and protects them from 20S proteasomal degradation. 
Although the relationship of NQO1 to the 20S proteasome remains unclear, this evidence 
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provide another possible explanation for the protective effects observed with NQO1 in 
chemical and radiation-induced carcinogenesis (203, 205-207).  
      Although NQO1 plays a protective role in the toxicity of many quinones, it can also 
reduce other quinones to unstable hydroquinones and give rise to ROS and toxicity (208). 
With some compounds, further rearrangement of the hydroquinone is possible leading to 
electrophile generation (209). Indeed, it has been shown that NQO1 can catalyze the 
reductive activation of many chemotherapeutic quinones such as mitomycins, diaziquone 
and benzoquinone ansamycins (209-213). Since NQO1 is overexpressed in many solid 
tumors, NQO1-targeted antitumor agents have attracted interests over the years (214). 
However, considering NQO1 is also distributed in many normal tissues including lung, 
liver, colon, breast and brain, the use of such agents may give rise to toxicity.  
Purpose and significance of the study 
     This study aimed to elucidate potential novel mechanisms of quinone toxicity at the 
level of protein handling. Three representative model quinones were used: 1,4-
benzoquinone BQ, 1,4-naphthoquinone MD and the dopamine derived o-quinone AC. 
BQ can be generated metabolically after exposure to benzene as well as be produced 
from chemical reactions in the environment (215, 216). MD is synthesized as an analog 
of vitamin K and it was recently found to exert anti-cancer therapeutic effects (15, 217). 
Clinically, MD is also being tested with respect to its use in alleviating EGFR inhibitor 
induced skin toxicities (ClinicalTrials.gov identifier: NCT01393821). Although the 
mechanisms of quinone toxicity including BQ, MD and AC have been extensively 
studied, the involvement of protein handling changes in quinone mediated toxicity have 
not been investigated in detail. These redox active and electrophilic quinones are likely to 
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target cysteine and lysine rich protein handling systems such as the proteasome. 
Modulation of a protein degradation system could strikingly amplify the consequences of 
a single quinone-induced arylation or oxidative event (Fig. 1.8). 
 
Figure 1.8 Quinones can undergo arylation and redox cycling reactions directly damaging 
proteins involved in protein handling leading to amplification of damage to many 
proteins. 
 
     Given the potential importance of proteasomal inhibition in the biogenesis of protein 
aggregates in PD, and the key role of the proteasome in regulation of compensatory 
protein handling systems, this study was also extended to define AC induced proteasomal 
inhibition and its relationship to the sequence of changes in other protein handling 
systems, including autophagy, ER stress response, heat shock response and aggresome 
formation. These experiments were performed to provide a better understanding of 
accumulation of protein aggregates in PD associated with dopamine-derived AC induced 
proteasomal inhibition.  
      Therefore, the following aims were proposed in the current study:  
      A. To characterize the activation sequence of changes in all major protein handling 
systems after proteasomal inhibition. The goal was to track changes in protein handling 
systems that occured subsequent to proteasomal inhibition by the established proteasome 
inhibitor MG132 and to characterize their relationship to toxicity.  
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      B. 1) To define protein handling changes induced by BQ, MD and AC; 2) To 
characterize the role of NQO1 in modulating quinone induced protein handling changes 
and toxicity. Although NQO1 has been suggested in protection against quinone toxicity, 
the role of NQO1 in modulation of quinone mediated protein handling changes has not 
been investigated. In this study, cells that stably overexpressed with human NQO1 have 
been generated and were used to define the role of NQO1 as a susceptibility factor for 
quinone toxicity. 
     C. Evaluation of the ability of 19BQA Hsp90 inhibitors to modulate protein handling 
systems that protect against mutant A53T α-synuclein induced toxicity. Novel 19BQA 
Hsp90 inhibitors have been developed in collaborative work between our lab and 
Professor Christopher J. Moody, University of Nottingham UK. The ability of 19BQAs 
to modify protein handling systems and induce toxicity in 5Y cells were defined. Using 
transient transduction of 5Y cells with adenovirus expressing human A53T α-synuclein, a 
PD cellular model was established as a model system to investigate A53T α-synuclein 
oligomer formation and toxicity. The ability of 19BQAs to protect against A53T α-
synuclein induced aggregation and toxicity and relationships with changes in protein 










THE ACTIVATION SEQUENCE OF CELLULAR PROTEIN HANDLING 





Considerable attention has been focused on protein handling in PD given the critical 
role of α-synuclein aggregation in disease etiology (29, 130, 132, 218). Although the 
molecular mechanism of loss of dopaminergic neurons is not fully understood, 
dysfunction of the UPS has been proposed as an important factor in the pathogenesis of 
both familial and sporadic PD (29, 131-133). In addition, it has been demonstrated that 
dopaminergic metabolites can cause inhibition of the proteasome leading to impaired 
protein handling (12, 219). Finally, a number of animal models have emphasized the role 
of the UPS and overall protein handling in the pathogenesis of PD (220-222). A 
comprehensive recent review has summarized the role of protein handling systems in PD 
(223).  
Although the ER stress response/UPR, autophagy, HSP response and aggresome 
formation have all been implicated respectively as compensatory mechanisms that occur 
downstream of proteasomal inhibition (72, 73, 125, 126, 224), little is known about the 
interrelationship between proteasomal inhibition and other cellular protein handling 
systems, especially with respect to the sequence of activation of these systems when 
stressed cells are challenged with accumulated proteins. The majority of studies to date 
have assessed one or two markers of protein handling may potentially lead to conflicting 
data regarding the involvement of protein handling mechanisms in toxicity. This study 
1
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was therefore conducted to define, in a comprehensive manner changes in all major 
protein handling systems subsequent to treatment with the proteasomal inhibitor MG132. 
Disturbances in protein handling are considered to be crucial in neurodegenerative 
diseases in general but PD in particular (29, 131-133). Since loss of dopaminergic 
neurons is an established characteristic of the pathology of PD, dopaminergic cells were 
used in this study to define changes in protein handling systems downstream of 
proteasomal inhibition. Moreover, which system(s) participated in the clearance of 
ubiquitin containing protein aggregates under conditions of impaired proteasomal activity 
was also examined.  
Materials and methods 
Materials and antibodies 
Pepstatin A, leupeptin, tunicamycin, chloroquine diphosphate salt, ammonium 
chloride and 3-methyladenine were obtained from Sigma Chemical (St. Louis, MO, 
USA). MG132, mouse monoclonal anti-Hsp27, anti-Hsp70 antibodies and rabbit 
polyclonal anti-Hsp90α antibody were purchased from Enzo (Farmingdale, NY, USA). 
The fluorescently labeled proteasome substrate Suc-Leu-Leu-Val-Tyr-AMC was 
obtained from Bachem (Torrance, CA, USA). Both proteasome inhibitor and substrate 
were dissolved in dimethyl sulfoxide. Rabbit polyclonal anti-tyrosine hydroxylase 
(AB152) was purchased from Millipore (Temecula, CA, USA). Mouse monoclonal anti-
vimentin (clone V-9) was obtained from Neomarkers (Thermo Scientific, USA). Rabbit 
polyclonal anti-LC3 (NB100-2331) was obtained Novus (Littleton, CO, USA). Rabbit 
polyclonal anti-phospho-eIF2α (Ser51, #9721), anti-eIF2α (#9722), anti-caspase-3 
(#9662) and mouse monoclonal anti-CHOP (#2895) antibodies were purchased from Cell 
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Signaling (Danvers, MA, USA). Rabbit polyclonal antibody targeting both the α and β 
subunits of the 20S proteasome were obtained from Abcam (Cambridge, MA, USA).  
Cell culture and treatment 
Immortalized rat mesencephalic dopaminergic cells (N27) were obtained from Dr. 
Curt Freed, Department of Clinical Pharmacology and Toxicology, University of 
Colorado Anschutz Medical Campus, Aurora CO (225). N27 cells were cultured in 
RPMI-1640 media (Cellgro, Manassas, VA, USA) containing 10% (v/v) fetal bovine 
serum, 100U/ml penicillin and 100µg/ml streptomycin (Cellgro, Manassas, VA, USA) in 
a humidified atmosphere of 5% CO2 at 37°C.  
Proteasomal activity assay 
Proteasomal activity was determined in N27 cells by measuring the fluorescence of 
cleaved substrate Suc-Leu-Leu-Val-Tyr-AMC (chymotrypsin-like activity) as described 
previously (58, 226). Following treatment with MG132 cells were lysed with proteasomal 
activity assay buffer (50mM Tris-HCl, pH 7.5, 250mM sucrose, 1mM dithiothreitol, 
5mM MgCl2, 2mM ATP, 0.5mM EDTA and 0.025% (w/v) digitonin) and then 
centrifuged at 10,000g for 14min at 4°C. The supernatants were collected and protein 
concentrations were determined using the method of Lowry
 
(227). To determine 
proteasome activity 20µg of cell lysate was incubated with 100µM fluorogenic peptide 
probe in proteasomal activity assay buffer (200µl) at 37°C. After 30min the reactions 
were stopped by the addition of 200µl ice-cold ethanol and the samples were centrifuged 
at 10,000g for 4min. The supernatant was transferred to a 96-well plate and the 
fluorescence of liberated 7-amino-4-methylcoumarin (Ex: 380nm; Em: 460nm) was 
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measured using a fluorescence micro-plate reader (Molecular Devices, Sunnyvale CA, 
USA). 
Immunoblot analysis 
Following treatment with MG132 cells were washed with phosphate buffered saline 
(PBS) and then lysed with RIPA buffer (50mM Tris-HCl, pH 7.4, 150mM NaCl, 0.1% 
(w/v) SDS, 1% (v/v) NP-40, 0.5% (w/v) sodium deoxycholate) supplemented with 
protease inhibitors (Complete, Mini Protease Inhibitor Cocktail, Roche, Germany) and 
phosphatase inhibitors (Sigma Chemical, USA). Cells were sonicated briefly on ice and 
then centrifuged at 10,000g for 14 min at 4°C. The supernatants were collected and 
protein concentrations were determined by the method of Lowry (227). Proteins were 
diluted in 2X Laemmli SDS sample buffer and heated to 70°C for 5 min. Proteins were 
separated using either a 7.5% (polyubiquitinated proteins) or 12% SDS-PAGE precast 
minigel (BioRad Laboratories, Hercules, CA, USA) Proteins were transferred to PVDF 
membranes in 25mM Tris, 192mM glycine containing 20% (v/v) methanol at 120mA for 
4h at 4°C. Membranes were blocked for 1h at room temperature in 10mM Tris-HCl, pH 
8.0, 150mM NaCl, 0.2% (v/v) Tween-20 (TBST) containing 5% (w/v) non-fat dry milk. 
Membranes were incubated with primary antibodies overnight at 4°C. Membranes were 
then washed extensively in TBST for 1h and then probed with HRP-conjugated goat anti-
rabbit or HRP-conjugated goat anti-mouse IgG (1:5000; Jackson Immunoresearch Labs, 
West Grove, PA, USA) for 30min at room temperature. Membranes were washed three-
times in TBST and protein bands were visualized using enhanced chemiluminescence 
(Thermo Scientific, USA).  
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Analysis of apoptosis  
Apoptosis was measured using FITC-conjugated anti-annexin V antibody and 
propidium iodide (PI). The FITC-conjugated anti-annexin V antibody was purchased 
from Invitrogen (Carlsbad, CA, USA) and binding buffer was obtained from BioLegend 
(San Diego, CA, USA). After the indicated duration of treatment with MG132, both 
attached floating cells were collected and pelleted by centrifugation at 10,000g for 5 min. 
Cell pellets were gently resuspended in 500µl annexin V binding buffer and incubated 
with anti-annexin V (2µl) and PI (1µl of 100µg/ml stock in phosphate-buffered saline) for 
10 min at 37°C in the dark. Samples were processed on ice and analyzed on a BD 
Biosciences FACS Calibur Flow Cytometer (San Jose, CA, USA) measuring 
fluorescence emission at 530nm (FL1, FITC) and PI at above 600nm (FL2). FL1 and FL2 
were collected on log-scale with voltages of 423 and 376, respectively. Signal overlap 
was adjusted and compensated. Data was acquired and analyzed using Cellquest software 
(Becton-Dickenson, Mountainview, CA, USA). 
Immunocytochemistry and quantification of aggresomes 
Sub-confluent N27 cells were grown on glass coverslips and treated with MG132 for 
the indicated times. Cells were then washed three times with PBS and fixed in 3.7% (v/v) 
formaldehyde in PBS for 12min. After washing with PBS, cells were permeabilized with 
0.1% (v/v) Triton X-100 in PBS for 10min, and then washed extensively with PBS and 
incubated in blocking buffer (RPMI1640 +10% (v/v) FBS) for 1h. Cells were incubated 
with anti-ubiquitin antibody (1:100); anti-vimentin antibody (1:1000); mouse anti-
Hsp70/72 antibody (1:1000) overnight at 4°C. Cells were then washed three times in 
TBST and incubated with secondary antibodies Alexa Fluor 594 conjugated goat anti-
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rabbit IgG (1:1000) and Alexa Fluor 488 conjugated goat anti-mouse IgG (1:2000) for 30 
min. DAPI (1µg/ml) was included with the secondary antibodies for nuclear staining. 
Coverslips were sequentially washed three times with TBST then once in deionized water 
and mounted on glass slides using SuperMount (BioGenex, USA). Cells were viewed on 
a Nikon TE2000 microscope with a Nikon C1 confocal imaging system. In control 
studies no significant immunostaining was observed in the absence of primary antibodies 
(data not shown). The number of aggresome (both ubiquitin and vimentin positive 
staining aggregates) was quantified by counting 100 cells in 20 random fields of each 
coverslip. Results shown are an average of at least 3 independent experiments for each 
treatment.  
Statistical analysis 
All experiments were repeated at least three times, and the values were expressed as 
means ± standard deviation (SD). The statistical significance was determined using Prism 
6.0 software (GraphPad Software, San Diego, CA). One-way analysis of variance 
(ANOVA) followed by the Tukey or Dunnet’s multiple comparison tests was used.  
Results 
Exposure to MG132 induced caspase 3 cleavage and toxicity in N27 cells 
 MG132 is a commonly used reversible proteasome inhibitor (40). It is tripeptide 
aldehyde and enters cell rapidly. The potential toxicity of proteasomal inhibition was first 
examined using MG132 in rat dopaminergic N27 cells. A low concentration of MG132 
(1µM) was sufficient to inhibit specifically the chymotrypsin-like activity of the 
proteasome in cell culture without affecting other proteases (40, 228). It was found that 
MG132 induced time-dependent apoptosis in N27 cells.  
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Figure 2.1 Time course of MG132 induced  cytotoxicity. The induction of apoptosis and 
necrosis was measured in N27 cells at 6 and 24h following treatment with MG132 
(1µM). (A) The representative immunoblot shows caspase 3 cleavage increased to a 
significant level at 24h. (B) Fold changes of cleaved caspase 3 are normalized by control 
and estimated by densitometry. (C) Apoptosis was also measured in N27 cells using 
annexin V/PI cell staining in combination with flow cytometry. Significant apoptosis and 
necrosis were observed after 24h treatment. These data are presented as mean ± SD, 
(n=3-6); **p<0.01 and ***p<0.001 are considered significant by ANOVA using 
Dunnet’s multiple comparison test.  
As shown in Figure 2.1 A and B, treatment with MG132 resulted in a detectable 
increase of cleaved caspase 3 which reached a significant level at 24h. Using flow 
cytometric analysis, it was further confirmed that low dose of MG132 induced significant 
apoptotic cell death at 24h with more than 40% of cells staining positive for Annexin V 
(Fig. 2.1 C). Moreover, after 6h exposure to MG132, an increased level of PI positive 
cells (necrosis) was observed and the percentage of necrosis increased to 30% at 24h 
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(Fig. 2.1 C), suggesting that necrosis accompanied the apoptogenic activity of MG132. 
No significant induction of either apoptosis or necrosis after 2h and 4h exposure to 
MG132 was detected suggesting that proteasomal inhibition induced both apoptosis and 
necrosis in a time-dependent manner in N27 cells.  
MG132 inhibited proteasomal activity and induced the accumulation of 
polyubiquitinated proteins in a time-dependent manner in N27 cells 
A time-course study was conducted to investigate the action of MG132 in N27 cells. 
The enzymatic activity of proteasome was determined by measuring the cleavage of the 
specific fluorogenic substrate Suc-LLVY-AMC (chymotrypsin-like activity) at 
380nm/460nm as previously described (58). After 10min exposure to MG132, 
proteasomal activity in N27 cells was rapidly decreased by 40% and only 20% of 
proteasomal activity remained after 24h treatment (Fig. 2.2 A). No significant differences 
in proteasomal activity were found between 2h and 24h treatments (Fig. 2.2 A) 
suggesting that exposure to low dose of MG132 (1µM) for 2h was sufficient to impair the 
majority of proteasomal activity in N27 cells. Accumulation of high molecular weight 
(HMW) polyubiquitinated proteins has been used as an indicator of proteasomal 
inhibition (229). To examine whether proteasome inhibition resulted in the accumulation 
of HMW polyubiquitinated proteins in N27 cells, immunoblot analysis was performed on 
whole cell lysates following MG132 treatment. HMW polyubiquitinated proteins could 
be detected after exposure to MG132 for 10min and increased to a more significant level 
at 24h (Fig.2.2 B), which correlated with the results of proteasomal activity assay (Fig. 
2.2 A).  
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Figure 2.2 Time course of proteasome inhibiton following treatment with MG132. 
Proteasesome activity. (A) and the accumulation of HMW polyubiquitinated proteins (B) 
were measured in N27 cells after treatment with MG132 (1µM). The proteasome activity 
was quantified by measuring fluorescence of Suc-Leu-Leu-Val-Tyr-AMC 
(chymotrypsin-like activity) cleavage at 380/460nm. The data is presented as mean ± SD, 
(n=3). ***p<0.001 is considered significant by one way analysis of variance (ANOVA) 
using Dunnet’s multiple comparison test. (B) The representative immunoblot blot shows 
time-dependent accumulation of HMW polyubiquitinated proteins and β-actin was 
included as a loading control. 
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Induction of the ER stress response was tightly associated with early proteasomal 
inhibition in N27 cells 
Recently, it has been shown that PERK and phosphorylated eIF2α co-localized with 
α-synuclein positive Lewy bodies in neurons of PD patients (230). Therefore, this study 
examined whether the PERK/eIF2α pathway was activated in response to proteasomal 
inhibition in dopaminergic cells. As shown in Figure 2.3 A and B, eIF2α was rapidly 
phosphorylated  after  10min  exposure to  MG132 (1µM) and the levels of p-eIF2α  were  
 
Figure 2.3 Time course of the activation of the ER stress response following treatment 
with MG132. N27 cells were treated with MG132 (1µM) then processed for immunoblot 
analysis for phospho-eIF2α (Ser-51), eIF2α and CHOP. Treatment with tunicamycin (Tn, 
3µM) was included as a positive control for ER stress and β-actin was included as a 
loading control. (A, B) Phosphorylation of eIF2α following treatment with MG132 
increased to a significant level at 2h. (C, D) Increases in CHOP reached a significant 
level at 4h. (B)(D) Fold changes of the indicated protein levels are normalized by control 
and estimated by densitometry. These data are presented as mean ± SD, (n=3); *p<0.05, 
**p<0.01 and ***p<0.001 are considered significant by ANOVA using Dunnet’s 
multiple comparison test. 
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significantly increased at 2h as determined by densitometry analysis. Induction of CHOP, 
a down-stream signal of p-eIF2α, could be detected at 2h and accumulated to a significant 
level after exposure to MG132 for 4h (Fig. 2.3 C, D). Tunicamycin (Tn) was included as 
a positive control for the induction of ER stress (231). These data indicated that 
proteasomal inhibition could rapidly trigger the ER stress response in N27 cells. 
Proteasomal inhibition induced autophagy 
Since the autophagic flux in N27 cells has not been determined using lysosome 
protease inhibitors in previous studies of autophagy, initial experiments was performed to 
define whether N27 cells were autophagy competent. As shown in Figure 2.4 A, the 
expression of LC3 II, an indicator of autophagy (232, 233), increased after serum 
starvation of N27 cells for 2h. However, the levels of LC3 II decreased after 4h serum 
starvation (Fig. 2.4 A, left) suggesting that the turnover of autophagic flux was an early 
event. Moreover, combined treatment of cells with serum starvation (2h) and different 
lysosome protease inhibitors (pepstatin A, P, leupeptin, L and ammonium chloride) could 
result in a further increase in LC3 II accumulation (Fig. 2.4 A, right). These data 
demonstrated that N27 cells were autophagy competent. 
 To determine the relationship between proteasomal inhibition and autophagy, the 
same time-course study of MG132 (1µM) was conducted. Data showed that the 
accumulation of LC3 II was not significantly increased until 4h following treatment with 
MG132 (Fig. 2.4 B, C). To further distinguish whether the increased levels of LC3 II by 
MG132 were due to upregulation of autophagosome or blockage of autophagic 
degradation (232), the lysosome inhibitor chloroquine (CQ) was used. CQ can inhibit the 
fusion of lysosome with autophagosomes that can in turn block autophagic degradation. 
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Treatment with MG132 had no effect on LC3 II accumulation at early time points (10min 
to 2h) in the absence or presence of CQ (Fig. 2.4 D). After 4h exposure the levels of LC3 
II were elevated and increased to a much higher level in the presence of CQ (Fig. 2.4 D), 
excluding the possibility that the increased amount of LC3 II by MG132 was a result of 
blockage of autophagic degradation. These data demonstrated that proteasomal inhibition 
induced autophagy in N27 cells.  
 
Figure 2.4 Prolonged proteasomal inhibition by MG132 stimulated time-dependent 
autophagic flux. (A) N27 cells were confirmed to be autophagy competent. LC3 II 
accumulation is a marker for autophagosome formation. (B) The representative 
immunoblot shows autophagy induction following treatment with MG132 (1µM). (C) 
Significant accumulation of LC3 II could be detected at 4h and to a greater extent at 24h. 
Fold changes of LC3 II levels are normalized by control and estimated by densitometry. 
These data are presented as mean ± SD, (n=3); **p<0.01 and ***p<0.001 are considered 
significant by ANOVA using Dunnet’s multiple comparison test. (D) Induction of 
autophagy by MG132 was confirmed by co-incubation with CQ. Cells were exposed to 
MG132 (1µM) with or without the co-treatment of CQ for the indicated times and then 
processed for immunoblot analysis. Note that CQ is a specific lysosome inhibitor and 
could suppress the fusion of autophagosomes with lysosomes. The elevated levels of LC3 
II in the presence of CQ (>4h) excluded the possibility that MG132 stimulated 
autophagic flux was due to the blockade of autophagic degradation in N27 cells. 
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Prolonged proteasomal inhibition resulted in formation of aggresome-like inclusion 
bodies and induction of Hsp70 in N27 cells 
Double immunostaining in association with confocal microscopy was performed to 
examine the effect of proteasomal inhibition on the distribution of intracellular 
ubiquitinated proteins, and to determine how early aggresomes formed in N27 cells in 
response to proteasome inhibition. Aggresomes can be identified in cells by their 
characteristic perinuclear accumulation of ubiquitin positive and vimentin caged 
inclusion bodies (111). In untreated cells, ubiquitin was well distributed throughout the 
cytoplasm while vimentin filaments could be found transversing the cell body (Fig. 2.5 
A, a-c). In contrast, in cells that had been treated with MG132 for 24h (Fig. 2.5 A, g-i), 
vimentin was completely collapsed and redistributed to form a cage-like structure 
surrounding ubiquitin inclusion bodies in the perinuclear region. Intermediate changes in 
vimentin and ubiquitin distribution could be detected after incubation with MG132 for 
12h (Fig 2.5A, d-f). Notably, aggresomes could be detected but only significantly after 
treatment with MG132 for 6h (Fig. 2.5 B), suggesting that the formation of aggresomes 
was a relatively late event and was triggered by prolonged proteasomal inhibition in N27 
cells.  
The expression levels of Hsp70 and Hsp90 were also examined using MG132 (1µM). 
Consistent with previous findings, Hsp70 was not detectable in unstressed rat 
dopaminergic cells (100) whereas the level of Hsp70 increased after 4h exposure to 
MG132, and was further elevated to a more significant level at 6h and 24h (Fig. 2.5 C, 
D). While Hsp90 was constitutively expressed in untreated cells, it was not induced even 
after prolonged proteasomal inhibition (Fig. 2.5 C).  
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Figure 2.5 Prolonged treatment with MG132 resulted in aggresome formation.  
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Figure 2.5 Prolonged treatment with MG132 resulted in aggresome formation. (A) 
Aggresome formation was examined by confocal microscopy in N27 cell treated with 
MG132 (1µM) for 24h. Aggresomes were characterized as vimentin-caged, ubiquitin-
positive perinuclear inclusions. For these studies cells were either treated  with DMSO (a-
c) or MG132 (1µM, d-f) for 2h to 24h, then processed for confocal laser microscopy 
using double immuno-labeling with antibodies to ubiquitin (red) and vimentin (green). 
Nuclei were stained with DAPI (blue). Arrows (panels f, i) indicate aggresome-like 
inclusion bodies. In these studies no aggresomes could be found at early time points (2 
and 4h) after treatment with MG132. (B) Quantitative determination of aggresome 
formation. Cells were treated with MG132 (1µM) and at the indicated times the 
percentage of aggresome containing cells were determined by counting 100 cells across 
20 random fields. The data represents the means ± SD, (n=3). Scale bar 20µm. (**p<0.01 
and ***p<0.001, ANOVA using Dunnet’s post test). (C) Induction of Hsp70 but not 
Hsp90 following treatment with MG132. N27 cells were exposed to MG132 (1µM) from 
10min to 24h as indicated and cytosolic fractions were then analyzed by immunoblot 
analysis for Hsp70 and Hsp90. (D) Fold changes of Hsp70 levels are normalized by 
control and estimated by densitometry. These data are presented as mean ± SD, (n=3); 
**p<0.01 and ***p<0.001 are considered significant by ANOVA using Dunnet’s 















In addition to Hsp70 and Hsp90, Hsp27 and Hsp40 are also expressed in the human 
central nervous system and it has been reported that Hsp27 expression is protective 
against α-synuclein-induced toxicity (102).However, levels of Hsp27 and Hsp40 were not 
significantly altered in N27 cells by proteasomal inhibition as indicated by immunoblot 
analysis (data not shown). 
Involvement of autophagy, but not the ER stress response or HSP response, in the 
clearance of aggresomes during recovery from proteasomal inhibition 
      The previous data indicated that the ER stress response, autophagy, aggresome 
formation and Hsp70 were all activated in response to proteasomal inhibition prior to the 
earliest signs of the occurrence of cell death. After 6h exposure to MG132, it seems likely 
that all these protein-handling systems work cooperatively to deal with the accumulation 
of misfolded proteins and aggregates resulting from UPS impairment. To further 
elucidate which protein handling system played a major role in restoring intracellular 
protein homeostasis, a recovery study of MG132 was conducted. As shown in Figure 2.6 
A, proteasomal activity was inhibited by ~80% following treatment with MG132 for 6h 
and after 24h incubation with fresh medium in the absence of MG132, proteasomal 
activity was restored confirming the effect of MG132 on proteasome inhibition was 
reversible as previously reported (40). Since cell death started to be detected after 6h 
exposure to MG132 and increased to a more significant level at 24h (Fig. 2.1 B), the 
recovery experiment was performed after 6h and 24h. Interestingly, the amount of LC3 II  
was found to be elevated during the 24h recovery period in both sets of recovery 
experiments whereas the level of p-eIF2α, CHOP and Hsp70 were decreased and the 
expression of Hsp27, Hsp40 (data not shown) and Hsp90 was not changed (Fig. 2.6 B).  
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Figure 2.6 Autophagy was induced and associated with aggresome clearance during the 
recovery period of proteasomal inhibition.  
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Figure 2.6 Autophagy was induced and associated with aggresome clearance during the 
recovery period of proteasomal inhibition. (A) Treatment of N27 cells with MG132 
(1µM) inhibited proteasomal activity by greater than 80% after 6h and proteasome 
inhibition could be reversed following a 24h recovery in complete media in the absence 
of MG132. Proteasome activity was measured as described in Material and Methods. 
Results are presented as mean ± SD (n=3) (***p<0.001, by ANOVA using Dunnet’s post 
test). (B) Autophagy indicator LC3 II levels were elevated during the recovery process 
whereas biomarkers of the ER stress response/UPR and HSP responses were attenuated. 
Cells were treated with MG132 (1µM) for 6h or 24h, and then exposed to fresh medium 
(minus MG132) for the indicated recovery period. (C) Induction of autophagy during the 
recovery process. N27 cells were exposed to MG132 (1µM) in the presence or absence of 
CQ (50µM). After 6h, the cultured medium was exchanged with drug free medium for 
the indicated recovery period. Note that aggresomes were removed as indicated by the 
disappearance of HMW polyubiquitinated proteins in the bottom immunoblot of (C) as 
well as the number of cells with of ubiquitin and vimentin positive perinuclear inclusions 
















These results suggested that the restoration of proteasome activity and cellular recovery 
was associated with stimulated autophagic flux, but not the ER stress response or HSP 
chaperone activity.  
      To confirm the increase of LC3 II during the recovery period was not due to the 
blockage of lysosome-dependent autophagic degradation, cells were co-treated with CQ 
for 6h following by recovery incubation with fresh medium for 48h. Compared to 
MG132 treatment alone, a further elevation of LC3 II was observed in the presence of 
CQ within the 24h recovery period (Fig. 2.6 C, top), which confirmed the activation of 
autophagy. Moreover, the results showed that a decrease in the levels of LC3 II and 
polyubiquitinated proteins at the end of a 48h recovery period (Fig. 2.6 C) suggesting that 
the autophagy clearing process was completed. In addition, cells were devoid of ubiquitin 
and vimentin positive aggresomes following a 24h recovery (Fig. 2.6 D) indicating that 
autophagy may be involved in the clearance of polyubiquitinated aggregates resulting 
from proteasomal inhibition in N27 cells.  
Discussion 
      Data in this study demonstrated a link between proteasomal inhibition and alterations 
in other major intracellular protein handling systems. EIF2α was rapidly phosphorylated 
after MG132 exposure indicating that the induction of the ER stress response/UPR was 
tightly associated with early proteasomal inhibition. Accumulating evidence suggests a 
role for the ER stress response in both PD pathogenesis (230, 234) and in response to 
disruption of the UPS (126, 235). ER associated protein degradation occurs via the 
proteasome and consequently proteasomal inhibition blocks degradation of unfolded 
proteins resulting in ER stress and induction of a protective UPR. 
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Further aggravation of ER stress can trigger either apoptosis or necrosis (126, 236, 237), 
and in the current study, both apoptosis and necrosis could be observed in N27 cells after 
prolonged treatment with MG132.  
      Coupling of proteasomal inhibition to autophagy has been implicated in 
neurodegenerative diseases (72, 238). Results in this study are supportive of this 
hypothesis demonstrating that proteasomal inhibition by MG132 activated autophagy in 
N27 dopaminergic cells. Interestingly, the data suggested that activation of autophagy 
was a delayed response relative to activation of the ER stress response, and recent work 
examining the interrelationship of proteasomal inhibition and autophagy in prostate 
cancer cells has demonstrated similar findings (87). HSPs in neuronal cells play a 
protective role against protein misfolding (100). The induction of Hsp70 but not Hsp90, 
Hsp27 and Hsp40 could be detected in response to proteasomal inhibition, suggesting 
Hsp70 plays a major role in chaperone mediated defense mechanisms against protein 
misfolding triggered by UPS impairment.  
 The results in this study demonstrated that during the early phase of proteasomal 
inhibition, the ER stress response was activated to attenuate intracellular protein load, 
autophagy facilitated the clearance of misfolded protein aggregates and the molecular 
chaperone Hsp70 was upregulated to assist protein refolding. The formation of 
aggresomes was observed at later times after UPS impairment subsequent to 
accumulation of polyubiquitinated protein, suggesting that aggresome formation may act 
as a protective mechanism to segregate the toxic intracellular aggregates and is also 
consistent with previous speculation that Lewy bodies are generated due to aggresome 
related processes and often occur as a late event in PD (112).  
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 Autophagy is able to protect against aggregated proteins and aggresomes are 
substrates for autophagy (113, 121, 239). Importantly, the data demonstrated that 
autophagy, but not the ER stress response or HSP response, might be involved in the 
clearance of aggresomes during the proteasome recovery process in N27 cells. Although 
a previous study reported that proteasome subunits colocalized with aggresomes at the 
MTOC (240) and speculated that aggresomes might sequester misfolded proteins for 
proteasomal degradation, it has been suggested that large aggregates are poor substrates 
for the proteasome because they may be excluded from the proteasome core particle (241, 
242).  
 
Figure 2.7 The schematic presentation shows the activation sequence of major cellular 
protein handling systems. 
 In summary, this study defined the sequence of activation of protein handling 
systems after inhibition of the proteasome in dopaminergic N27 cells. The data suggested 
that the activation of diverse protein handling systems was a highly regulated process. 
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After proteasomal inhibition (Fig. 2.7), the ER stress response was most rapidly activated 
followed by autophagy and Hsp70 induction with subsequent formation of aggresomes.   
In addition, results suggested the protective role of autophagy but not other protein 
handling systems during recovery of the cell from proteasomal inhibition. These results 
indicated that the mechanisms of induction of alternate protein handling systems and their 
temporal relationship might be important parameters determining the extent of 
accumulation of misfolded proteins in cells as a result of proteasomal inhibition. 
Determination of the relationship between different protein handling systems should 
provide a better understanding of accumulation of protein aggregates in 
















QUINONE-INDUCED PROTEIN HANDLING CHANGES: IMPLICATIONS 





      Previous studies have attributed quinone-induced toxicity to two major mechanisms: 
1) ROS formation and 2) arylation of macromolecular targets including histone, tubulin, 
topoisomerase II, and DNA (18, 243, 244). However, few studies have reported quinone-
induced changes in major protein handling systems, which include the 20/26S 
proteasome, the ER stress response, autophagy, HSP response and aggresome formation. 
Although BQ has been shown to activate the PERK/eIF2α pathway of the ER stress 
response (14), whether these effects were due to quinone mediated ROS production or 
arylation and their relationship to other protein handling systems was not examined. 
Interestingly, earlier results by our lab and others have shown that AC inhibited 
proteasomal activity in an ROS-independent manner (12, 219, 245). In addition, both AC 
and BQ have been found to disrupt the microtubule network in cells which was 
associated with the formation of quinone adducts with tubulin (17, 128, 129). These data 
suggest an important role of arylation in quinone mediated protein handling changes. In 
this study, the 20/26S proteasome was hypothesized to be a good arylating target for 
quinones, because of its abundant concentrations in cytosol and its high content of 
cysteine and lysine residues. Duroquinone (DQ) and dimethoxy-naphthoquinone 
(DMNQ), are fully substituted analogs of BQ and MD respectively (Fig 3.1). Since DQ 
2
This chapter was published in Toxicology and Applied Pharmacology 280 (2014) 285–
295. http://dx.doi.org/10.1016/j.taap.2014.08.014 
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and DMNQ can still redox cycle but are incapable of arylation they were also utilized in 
these studies in an attempt to define the relative roles of arylation and oxidative stress in 



















Figure 3.1 Chemical structures of quinones utilized in this study. 
      Although NQO1 has been suggested to play a role in protection against the toxicity of 
many quinones, the role of NQO1 as a defense system against quinone mediated protein 
handling changes has not been examined. My earlier results have demonstrated that 
proteasomal inhibition could trigger the sequence of activation of other protein handling 
systems (246). This study was performed to further determine whether quinones induce 
changes in major protein handling systems either independently or downstream of 
proteasomal inhibition. Moreover, using an isogenic NQO1-overexpressing cell line, 
NQO1 was found to be a susceptibility factor for quinone induced ER stress responses 
and toxicity.  
Materials and methods 
Materials and antibodies 
1,4-benzoquinone (BQ), menadione (MD), duroquinone (DQ), 2,3-dimethoxy-1,4-
naphthoquinone (DMNQ), NADH, dopamine hydrochloride, ATP disodium salt, 
digitonin, phenylmethylsulfonyl fluoride (PMSF), tunicamycin, mouse monoclonal anti-
β-actin (A5441) and rabbit polyclonal anti-ubiquitin (U5379) antibodies were obtained 
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from Sigma Chemical (St. Louis, MO, USA). Polyphenol oxidase (mushroom tyrosinase, 
LS003793) was purchased from Worthington Biochemical (Lakewood, NJ, USA). 
Dithiothreitol was purchased from Fisher Scientific (Pittsburgh, PA, USA). MTT 
[Thiazolyl blue] was obtained from Research Products International (Mount Prospect, IL, 
USA). MG132, purified human 20S proteasome (BML-PW8720), mouse monoclonal 
anti-Hsp27, anti-Hsp70 antibodies and rabbit polyclonal anti-Hsp90α antibody were 
obtained from Enzo (Farmingdale, NY, USA). FITC / annexin V (640906) and annexin V 
binding buffer (422201) were purchased from BioLegend (San Diego, CA, USA). The 
fluorescently labeled proteasome substrate Suc-Leu-Leu-Val-Tyr-AMC was purchased 
from Bachem (Torrance, CA, USA). Rabbit polyclonal anti-LC3 (NB100-2331) was 
obtained Novus (Littleton, CO, USA). Mouse monoclonal anti-NQO1 (A180) antibody, 
rabbit polyclonal anti-phospho-eIF2α (Ser51, #9721), anti-eIF2α (#9722) and anti-
caspase-3 (#9662) antibodies were purchased from Cell Signaling Technology (Danvers, 
MA, USA). Rabbit polyclonal anti-caspase 12 (ab62484) and anti-NQO1 (ab34173) 
antibodies were obtained from Abcam (Cambridge, MA, USA).  
Cell culture and treatment 
N27 rat mesencephalic dopaminergic cells were obtained from Dr. Curt Freed, 
Department of Clinical Pharmacology and Toxicology, University of Colorado Anschutz 
Medical Campus, Aurora CO (225). N27 cells were cultured in RPMI-1640 medium 
(Cellgro, Manassas, VA, USA) containing 10% (v/v) fetal bovine serum, 100 units/ml 
penicillin and 100 µg/ml streptomycin (Cellgro, Manassas, VA, USA) in a humidified 
atmosphere of 5% CO2 at 37°C. Stock solutions of BQ and MD (10mM) were prepared 
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in ethanol and AC (1mM) was generated as described below. All stock solutions were 
used immediately after preparation. 
Stable transfection of N27 cells with human wild-type (wt) hNQO1 
These cells had been generated previously in the lab by Dr. Jadwiga Kepa. Stable 
transfection of N27 cells was carried out as described previously (198). Briefly, the 
CMV-driven mammalian expression vector pcDNA3 containing human NQO1*1 wild 
type cDNA was transfected by electroporation into N27 cells with neomycin as the 
selection marker. Clones were selected after 7 to 10 days and examined for both NQO1 
enzymatic activity and NQO1 immunoreactivity. The NQO1-transfected (clone 4) cells 
are routinely examined for NQO1 expression by activity assay, immunoblot analysis and 
confocal microscopy.  
Measurement of NQO1 activity 
NQO1 activity was determined spectrophotometrically in cell lysates using the 
dicumarol-inhibitable reduction of 2,6-dichlorophenol-indophenol (DCPIP) at 600 nm as 
described previously (247). Protein concentrations were determined using the method of 
Lowry (227). 
Aminochrome preparation  
Aminochrome was prepared by enzymatic reaction (300µl, room temperature) 
containing 3.3mM dopamine and 500µg tyrosinase in 25mM Tris-HCl buffer (pH 7.4). 
After 3min at room temperature the reaction mixture was centrifuged (13,000 rpm for 5 
min at 4°C) through a 100-kDa molecular mass cutoff membrane filter (Millipore 
Corporation, Bedford, MA) to remove tyrosinase and prevent additional tyrosinase-
catalyzed oxidative reactions. After centrifugation the filtrates were collected and stored 
 51 
on ice. To determine the concentration of aminochrome generated 5µl of the filtrate was 
added to 995µl of 25mM Tris-HCl buffer (pH 7.4) and the absorption was determined at 
474nm. The concentration of aminochrome was calculated using a molar extinction 
coefficient of 3,058 at 474nm (Baez et al., 1997). 
MTT growth inhibition assay  
Quinone toxicity was determined using the MTT assay. N27 cells were seeded at 
2000 cells per well in 96-well plates (in triplicate). After 24h the cells were treated with 
BQ or MD in complete medium or with AC in serum-free medium for 24h. After drug 
treatments, the medium were removed and replaced with MTT (1mg/ml) containing 
complete medium. After 4h the MTT containing medium was removed and the MTT 
formazan product was extracted from cells with dimethyl sulfoxide. The optical density 
of the extract was determined at 550nm with a microplate reader. IC50 values were 
defined as the concentration of quinone that resulted in a 50% reduction in cell density 
compared to untreated controls. 
Trypan blue exclusion assay 
Cells were seeded at 1.5×10
5
 cells into 60mm x 15mm tissue culture dishes in 3ml of 
complete medium and allowed to attach and grow for 2 days. Following treatment with 
quinone for the indicated times, cell pellets containing both floating and attached cells 
were collected and then resuspended in 1ml PBS. To assess cell viability the cell 
suspension (10µl) was stained with 10µl trypan blue dye (0.4% w/v in PBS). The number 
of trypan blue positive cells was determined using a Life Technologies Countess
TM
 




Apoptosis was determined by flow cytometry using FITC-conjugated anti-annexin V 
and propidium iodide (PI) as previously described (15, 246). After 24h treatment with 
quinones, cell pellets including both the floating and attached cells were collected and 
gently resuspended in 500µl of annexin V binding buffer and incubated with anti-annexin 
V antibody (2µl) and PI (0.7µl of 100µg/ml stock) for 10 min at 37°C in the dark. 
Samples were kept on ice, and then analyzed using a BD Biosciences FACS Calibur 
Flow Cytometer (San Jose, CA, USA). The fluorescence was measured at 530nm (FL1, 
FITC) and PI at above 600nm (FL2), and the data was acquired and analyzed using 
Cellquest software (Becton-Dickenson, Mountainview, CA, USA). 
Proteasomal activity assay 
Proteasomal activity was determined by measuring the fluorescence of cleaved 
proteasome substrate Suc-Leu-Leu-Val-Tyr-AMC (chymotrypsin-like activity), Boc-Leu-
Arg-Arg-AMC (trypsin-like activity) and Z-Leu-Leu-Glu-AMC (caspase-like activity) 
cleavage at 380/460nm as described previously (246). Briefly, purified human 20S 
proteasome (1.25µg) was incubated with vehicle or quinone in 100µl of proteasome 
activity assay buffer (50mM Tris-HCl, pH 7.5, 250mM sucrose, 1mM dithiothreitol, 
5mM MgCl2, 2mM ATP, 0.5mM EDTA and 0.025% (w/v) digitonin). Proteasome 
activity substrate (Suc-Leu-Leu-Val-Tyr-AMC, Boc-Leu-Arg-Arg-AMC or Z-Leu-Leu-
Glu-AMC 200µM) was then added. After 30min at 37°C 40µl of the above reaction was 
transferred to a 96-well plate and the fluorescence of liberated 7-amino-4-methyl 
coumarin (Ex: 380nm; Em: 460nm) was measured in duplicate samples. To measure 
intracellular proteasomal activity, cells were treated with quinones for the indicated 
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times, washed with PBS (10ml) three times, and then lysed with proteasomal activity 
assay buffer and centrifuged at 10,000g for 14min at 4°C. The supernatants were 
collected and protein concentrations were determined using the method of Lowry (227). 
To assay proteasome activity cell lysate (20µg) was added to 100µl of proteasome 
activity assay buffer followed by the addition of 100µM proteasome substrate Suc-Leu-
Leu-Val-Tyr-AMC. After 30min at 37°C the reactions were stopped by the addition of 2 
volumes of ice-cold ethanol and 40µl samples were transferred to a 96-well plate and the 
fluorescence of liberated 7-amino-4-methylcoumarin (Ex: 380nm; Em: 460nm) was 
measured in duplicate samples. 
Immunoblot analysis 
Following treatment with quinones cells were washed with phosphate buffered saline 
(PBS) and then lysed with RIPA buffer (50mM Tris-HCl, pH 7.4, 150mM NaCl, 0.1% 
(w/v) SDS, 1% (v/v) NP-40, 0.5% (w/v) sodium deoxycholate) supplemented with 
protease inhibitors (Complete, Mini Protease Inhibitor Cocktail, Roche, Germany), 
PMSF (2mM) and phosphatase inhibitors (Sigma Chemical, USA). Cells were sonicated 
on ice and then centrifuged at 10,000g for 14 min at 4°C. The supernatants were collected 
and protein concentrations were measured using the method of Lowry (227). Proteins 
were diluted in 2X Laemmli SDS sample buffer and heated to 70°C for 5 min, and then 
separated on a 12% SDS-PAGE precast minigel (BioRad Laboratories, Hercules, CA, 
USA). A 7.5% SDS-PAGE precast minigel was used to separate the high molecular 
weight polyubiquitinated proteins. Proteins were transferred to polyvinylidene fluoride 
membranes in 25mM Tris, 192mM glycine containing 20% (v/v) methanol at 4°C. 
Membranes were incubated in blocking buffer (10mM Tris-HCl, pH 8.0, 150mM NaCl, 
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0.2% (v/v) Tween-20 (TBST) containing 5% (w/v) non-fat dry milk) for 1h, and then 
incubated with primary antibodies overnight at 4°C. Membranes were washed every 
10min in TBST for 1h and then probed with horseradish peroxidase-conjugated goat anti-
rabbit or horseradish peroxidase-conjugated goat anti-mouse IgG (1:5000; Jackson 
Immunoresearch Labs, West Grove, PA, USA) for 30min at room temperature. 
Membranes were washed three times in TBST and protein bands were visualized using 
enhanced chemiluminescence (Thermo Scientific, USA).  
Immunocytochemistry for aggresome-like inclusion bodies   
Aggresome-like inclusion bodies were determined using immnostaining for ubiquitin-
positive aggregates as previously described (246). Sub-confluent N27 cells were grown 
on glass coverslips in 6-well plates and treated with quinones for the indicated times. 
Cells were washed three times with PBS and fixed in 3.7% (v/v) formaldehyde in PBS 
for 12min, and then permeabilized with 0.1% (v/v) Triton X-100 in PBS for 10min. After 
extensively washing with PBS, cells were incubated in blocking buffer (RPMI-1640 
containing 10% FBS) for 1h, and then incubated with anti-ubiquitin antibody (1:100) 
overnight at 4°C. Cells were then washed three times in TBST and incubated with Alexa 
Fluor 594 conjugated goat anti-rabbit IgG (1:1000, Jackson Immunoresearch Labs) 
containing DAPI (1µg/ml) for 30min. Coverslips were washed three times with TBST 
then rinsed in distilled water, inverted and mounted on glass slides using SuperMount 
(BioGenex, USA). Cells were viewed on a Nikon TE2000 microscope with a Nikon C1 




Intracellular oxidative stress  
Quinone-induced oxidative stress was determined using CellROX
®
 Green reagent 
(Life Technologies, Carlsbad, CA USA) in combination with confocal microscopy.  For 
these studies (sub-confluent) N27 and clone 4 cells were grown on glass coverslips in 6-
well plates. After treatment with quinones the medium was removed and cells washed 
three times with PBS. The CellROX
®
 Green fluorogenic probe (5µM in PBS) was added 
to cells for 30min at 37°C in the dark. Cells were washed three times with PBS then fixed 
in 3.7% (v/v) formaldehyde in PBS for 12min, and then permeabilized with 0.1% (v/v) 
Triton X-100 in PBS for 10min. After extensively washing with PBS cells were 
incubated in blocking buffer (RPMI-1640 containing 10% FBS) for 1h, and then 
incubated with anti-NQO1 antibody (1:100) overnight at 4°C followed by Alexa Fluor 
594 conjugated goat anti-rabbit IgG (1:1000) containing DAPI (1µg/ml) for 30min. 
Coverslips were washed three times with TBST then rinsed in distilled water, inverted 
and mounted on glass slides using SuperMount (BioGenex, USA). Cells were viewed on 
a Nikon TE2000 microscope with a Nikon C1 confocal imaging system.  
Oxygen consumption assay 
The ability of quinones to undergo redox cycling in N27 and clone 4 cells was 
determined using an airtight Clark electrode (Yellow Springs Instrument Company, 
Yellow Springs OH, USA). For these studies 3 million cells were suspended in 3ml cell 
culture medium at 37°C in the presence or absence of quinones and the rate of oxygen 
consumption was measured over 10min Dissolved oxygen concentrations were adjusted 
for altitude (5280 feet) and temperature (37°C).  
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Statistical analysis  
All experiments were repeated at least three times, and the values were expressed as 
means ± standard deviation (SD). The statistical significance was determined using Prism 
6.0 software (GraphPad Software, San Diego, CA). One-way analysis of variance 
(ANOVA) followed by the Tukey or Dunnet’s multiple comparison tests or two-way 
ANOVA by Bonferroni posttests was used.  
Results 
Inhibition of proteasomal activity by quinones 
The 20/26S proteasome contains three active sites (chymotrypsin-like, trypsin-like 
and caspase-like), however, it is the chymotrypsin-like site that contributes the most to 
the catalytic activity of the proteasome and is routinely used to measure proteasomal 
activity (40). The chymotrypsin-like activity of purified human 20S proteasome was 
measured following treatment with BQ, MD and the dopamine oxidation product AC for 
30min (Fig. 3.1). The results showed that both BQ and AC, but not MD, induced 
significant proteasomal inhibition in a dose-dependent manner (Fig. 3.2 A-C). DQ and 
DMNQ failed to exert any inhibitory effect on the proteasome (Fig. 3.2 A and B). The 
results with DMNQ were to be expected given the inability of MD to exert any inhibitory 
effect (Fig. 3.2 B), but the data obtained with DQ indicate a role for arylation in 
benzoquinone-induced proteasomal inhibition (Fig. 3.2 A).  
The inhibitory effect of quinones on intracellular proteasomal activity was confirmed 
using dopaminergic N27 cells. As shown in Figure 3.2 D and F, both BQ and AC induced 
dose-dependent proteasomal inhibition. Treatment with BQ (20µM) for 24 hours resulted 
in nearly 50% inhibition of proteasomal activity in N27 cells while AC (80µM) inhibited 
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over 60% of proteasomal activity (Fig. 3.2 D and F). It is noteworthy that AC did not 
inhibit proteasomal activity in N27 cells as markedly as the purified 20S proteasome (Fig. 
3.2 C and F) probably because in cells factors such as compound uptake and elimination 
as well as additional targets for alkylation may contribute to attenuate the level of 
proteasome inhibition. 
 
Figure 3.2 Inhibition of proteasomal activity by quinones. (A-C) The effect of quinones 
on purified human 20S proteasomal activity. BQ and AC inhibited the chymotrypsin-like 
active site of purified human 20S proteasome in a dose-dependent manner after 
incubation for 30 min. MD had no effect on 20S proteasomal activity. DQ and DMNQ, 
the fully substituted analogs of BQ and MD respectively, did not inhibit 20S proteasomal 
activity. (D-F) The effect of quinones on 20/26S proteasomal activity in N27 cells. BQ 
and AC, but not MD, significantly inhibited the chymotrypsin-like active site of 
intracellular 20/26S proteasomal activity in N27 cells at 24h. These data are presented as 
mean ± SD, (n=3); *p<0.05, **p<0.01 and ***p<0.001 are considered significant by one-
way ANOVA using Dunnet’s multiple comparison test.  
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Whether quinones affect the activities of the trypsin-like and caspase-like sites of the 
20S proteasome was also examined. Interestingly, AC could inhibit all three catalytic 
sites of the proteasome, whereas BQ had a greater inhibition on the trypsin-like active 
site, inhibited the chymotrypsin-like site to a lesser extent and had no effect on the 
caspase-like site (Fig. 3.3). Importantly, DQ had little effect on the activities of the 
trypsin-like and caspase-like sites of the proteasome that further confirmed a major role 
of arylation in BQ mediated proteasomal inhibition. Because inactivation of the 
chymotrypsin-like site but not the trypsin-like or caspase-like sites could significantly 
reduce protein breakdown (40, 248, 249), I therefore focused on the effect of quinones on 
the chymotrypsin-like site of the proteasome in this study. 
Notably, AC could induce greater proteasomal inhibition at an equivalent dose to BQ 
(Fig. 3.2 and 3.3). This effect may possibly be explained on the basis of the lowest 
unoccupied molecular orbital (LUMO) energy (ELUMO) value (in eV). Decreasing the 
energy of the LUMO, enhances the ability of a molecule to accept an electron into the 
LUMO. Several studies have applied ELUMO to predict a given molecule’s 
electrochemical properties and reactivity with biological nucleophiles (250, 251). The 
local absolute ELUMO values of BQ, AC and MD were calculated with Spartan '08 v1.2 
(Wavefunction, Inc.) as described previously (LoPachin et al., 2007). Results 
demonstrated that the carbonyl moiety on AC may be more likely to react with 
nucleophilic amino acids, as reflected by a greater absolute ELUMO value, relative to the 
corresponding carbonyl sites on BQ and MD (Fig. 3.4). In addition, the calculation of 
electrophile softness which correlates most closely with reactivity with soft nucleophiles 
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such as cysteine demonstrated that AC (0.602) was a softer electrophile than either BQ 
(0.524) or MD (0.498) which may also contribute to its greater reactivity. 
 
Figure 3.3 The effects of quinones on three specific protease activities in purified human 
20S proteasome. Purified human 20S proteasome were incubated with BQ, DQ, MD 
DMNQ and AC at the indicated doses and the proteasomal activity was quantified by 
measuring fluorescence of Suc-Leu-Leu-Val-Tyr-AMC (chymotrypsin-like activity), 
Boc-Leu-Arg-Arg-AMC (trypsin-like activity) and Z-Leu-Leu-Glu-AMC (caspase-like 
activity) cleavage at 380/460nm. These data are presented as mean ± SD, (n=3). *p<0.05, 
**p<0.01 and ***p<0.001 are considered significant by two-way ANOVA using 
Bonferroni  posttests. 
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Figure 3.4 The amplitude of the ELUMO mapped onto the electron density surface 
indicates which regions are most likely to accept electrons from protein nucleophiles. The 
lowest unoccupied molecular orbital (LUMO) energy (ELUMO) was calculated with 
Spartan '08 v1.2 (Wavefunction, Inc.) as described previously (LoPachin et al., 2007). 
The electron density surfaces of BQ (left panels), AC (middle panels), and MD (right 
panels) are mapped with the amplitude of the local ELUMO values (in eV) using a 
standardized rainbow gradient from red (lowest) to blue (highest). The values and 
location of the absolute maximum are indicated and suggest that the indicated carbonyl 
moiety of AC has a greater propensity to react with critical nucleophilic amino acids in 
the 20S proteasome compared to those of BQ or MD. 
BQ induced proteasomal inhibition was tightly associated with induction of the ER 
stress response and autophagy, but had little effect on other major protein handling 
systems (HSPs and formation of aggresome-like inclusion bodies) 
Since quinones including BQ and AC were able to inhibit proteasomal activity, a 
detailed time-course study was conducted to characterize other biochemical changes 
induced by quinones in N27 cells and to dissociate any changes in protein handling from 
toxicity. Treatment of cells with BQ for 24h resulted in the loss of cell viability in a dose-
dependent manner (Fig. 3.5 A). A dose of BQ (20µM) was sufficient to cause 50% of cell 
death at 24h. After a 10 min exposure to BQ (20µM) a rapid decrease (30%) in 
proteasomal activity was observed and the inhibitory effect was sustained up to 24h (Fig. 
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3.5 B). Moreover, after treatment with BQ for 10min we were able to detect the 
accumulation of HMW polyubiquitinated proteins, an indicator of proteasomal inhibition 
(Fig. 3.5 C), confirming proteasomal inhibition induced by BQ was an early event.  
      BQ induced changes in other protein handling systems were also examined using 
phosphorylation of elF2α (p-elF2α) and LC3 II accumulation as biomarkers of the ER 
stress response and autophagy, respectively. As shown in Figure 3.5 D, exposure to BQ 
for 10min increased the expression of p-elF2α and LC3 II indicating that the ER stress 
response and autophagy were rapidly activated. However, a subsequent decrease in p-
elF2α expression at later time points was observed following treatment with BQ and this 
might be due to the fact that BQ is highly reactive and can be rapidly detoxified as 
previously reported (14). Notably, no toxicity following BQ treatment could be detected 
at the early time points of 10min, 30min and 2h as indicated by trypan blue exclusion 
assay or by flow cytometry analysis of apoptosis/necrosis (Fig. 3.6) where marked 
changes in proteasomal inhibition and the ER stress response and autophagy were 
observed (Fig. 3.5). MG132 was included as a positive control for proteasomal inhibition. 
Interestingly, treatment with tunicamycin (Tn), a positive control for induction of ER 
stress in this study also induced LC3 II accumulation. Since phosphorylation of eIF2-a 
has been shown to regulate autophagy formation (85) there may be crosstalk between the 
ER stress and autophagy pathways. 
      It is noteworthy that after exposure to BQ for 2h the amount of LC3 II decreased 
while the polyubiquitinated proteins did not accumulate further (Fig. 3.5 C and D). It is 
possible that the early induction of autophagy plays a role in the decreased accumulation 
of polyubiquitinated proteins observed at later time points. In these studies BQ was not 
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able to induce the formation of aggresome-like inclusion bodies or cause significant 
induction of HSPs including Hsp27, Hsp70 (not detectable) and Hsp90 (Fig. 3.5 D).  
 
Figure 3.5 BQ inhibited proteasomal activity and further activated the ER stress response 
and autophagy. (A) Growth inhibition in N27 cells upon treatment with BQ. Cells were 
incubated with increasing concentration of BQ (0-80µM) for 24h and cell viability was 
assessed by the MTT assay. (B) The inhibition of proteasomal activity by BQ (20µM) 
occurred at early time points in N27 cells. (C) The representative immunoblot blot shows 
that as early as 10min BQ induced accumulation of higher molecular weight 
polyubiquitinated proteins. (D) Time course of the ER stress response and autophagy 
following treatment with BQ. Treatment (24h) with tunicamycin (Tn, 3µM) and MG132 
(1µM) were included as positive controls. β-actin was included as a loading control. 
Values in (A) and (B) are presented as mean ± SD, (n=3); **p<0.01 is considered 
significant by one-way ANOVA using Dunnet’s post test. 
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Figure 3.6 No toxicity was observed following treatment with BQ at the early time points 
of 10min, 30min and 2h. (B) Cells were treated with BQ at 20 µM for 10min up to 24h 
and harvested for determination of cell number by using a trypan blue exclusion assay. 
(C) Apoptosis was measured using annexin V/PI cell staining in combination with flow 
cytometry in cells after exposure to BQ (20 µM) for 10min up to 24h. These values are 
presented as mean ± SD, (n=3); *p<0.001 is considered significant by one-
way ANOVA using Dunnet’s post test. 
Dopamine derived AC triggered the ER stress response, induction of autophagy and 
formation of aggresome-like inclusion bodies in N27 cells 
Because AC is unstable and readily reacts with protein thiols including those in fetal 
bovine serum, N27 cells were incubated with AC in serum free medium as previously 
reported (16). Treatment with AC led to dose-dependent cytotoxicity and exposure to a 
dose of 80µM of AC resulted in over 50% cell death (Fig. 3.7 A). The same time-course 
study used for BQ was then conducted to examine the effect of AC on the activities of 
major protein handling systems and to dissociate protein handling changes from toxicity. 
As shown in Figure 3.7 B, AC (80µM) inhibited proteasomal activity in a time-dependent 
manner and resulted in a significant decrease in activity at 2h. Accordingly, the 
accumulation of polyubiquitinated proteins was detected at 2h following treatment with 
AC (Fig. 3.7 C).  
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Treatment of N27 cells with AC did not cause changes in the expression of Hsp27, 
Hsp70 (not detectable) and Hsp90 (Fig. 3.7 D), however, rapid activation of the ER stress 
response and autophagy was observed. As shown in Figure 3.7 D and E, the protein 
levels of p-elF2α and LC3 II were induced in a time-dependent manner following 
treatment with AC from 10min up to 24h and significant increases could be detected at 
2h. These results suggested that the activation of the ER stress response and autophagy 
were tightly associated with AC induced proteasomal inhibition. In addition, both 
perinuclear and more diffuse aggresome-like inclusion bodies containing ubiquitin were 
found in N27 cells after prolonged 24h treatment with AC (Fig. 3.7 F). To ensure 
ubiquitin containing aggresome-like inclusion bodies are distinct from LC3 containing 
autophagosomes, cells were double immunostained with anti-LC3 and anti-ubiquitin 
antibodies. No co-localization of ubiquitin and LC3-positive puncta could be detected 
(Fig. 3.8) demonstrating that the AC induced ubiquitin-positive, aggresome-like inclusion 
bodies were not autophagosomes. These studies indicated that AC was more reactive than 
BQ in terms of perturbing a greater number of intracellular protein handling systems and 
the results demonstrated for the first time that AC was able to trigger the ER stress 
response and aggresome formation. 
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Figure 3.7 Dopamine derived AC triggered the ER stress responses, turnover of 













Figure 3.7 Dopamine derived AC triggered the ER stress responses, turnover of 
autophagic flux and formation of aggresome-like inclusion bodies in N27 cells. (A) 
Growth inhibition in N27 cells upon treatment with AC. Cells were incubated with 
increasing concentrations of AC (0-80µM) for 24h and cell viability was assessed using 
the MTT assay. (B) AC (80µM) inhibited proteasomal activity in a time-dependent 
manner in N27 cells. Values in (A) and (B) are expressed as mean ± SD of 3 
determinations. *p<0.05, **p<0.01 and ***p<0.001  are considered significant by one-
way ANOVA using Dunnet’s post test. (C) The representative immunoblot blot shows 
AC induced the time-dependent accumulation of polyubiquitinated proteins. (D) Time 
course of the ER stress response and autophagy following treatment with AC (80µM). 
Treatment (24h) with tunicamycin (Tn, 3µM) and MG132 (1µM) were included as 
positive controls. β-actin was included as a loading control. Untreated cells in complete 
medium is labeled as C(S+), or in serum free medium as C(S-). (E) Fold changes of p-
eIF2α (A) and LC3 II (B) levels are normalized to controls and estimated by 
densitometry. Note that significant accumulation of p-eIF2α and LC3II could be detected 
in N27 cells after treatment with AC (80µM) for 2h. These data are presented as mean ± 
SD, (n=4); *p < 0.01 and **p < 0.001 are considered significant by ANOVA using 
Dunnet’s multiple comparison test. (F) AC induced formation of ubiquitin positive 
aggresome-like inclusion bodies in N27 cells. After exposure to AC (80µM) for 24h, 
cells were fixed and immunostained for ubiquitin (red) and nuclei (DAPI, blue). Note that 
aggregates of ubiquitinated proteins are observed near the perinuclear region (white 




Figure 3.8 AC induced LC3-positive puncta as evidence for autophagosome formation. 
After treatment with AC (80µM) for 24h, cells were fixed and immunostained for 
ubiquitin (red), LC3 (green) and nuclei (DAPI, blue). Note that ubiquitin inclusion bodies 
(white arrow) and LC3-positive puncta (orange arrow) could be detected respectively but 
they were not colocalized demonstrating that the AC induced ubiquitin-positive, 
aggresome-like inclusion bodies were not autophagosomes. The lysosome inhibitor 
chloroquine (CQ) could increase the formation of LC3 positive puncta and was used as a 
positive control for autophagosome staining. The proteasome inhibitor MG132 was 
included as a positive control for ubiquitin positive aggresome formation. Similar to the 
data found with AC, MG132-induced, LC3-positive puncta were not colocalized with 






Figure 3.9 No toxicity was observed following treatment with AC at the early time points 
of 10min, 30min and 2h. (B) Cells were treated with AC at 80 µM for 10min up to 24h 
and harvested for determination of cell number by using a trypan blue exclusion assay. C) 
Apoptosis was measured using annexin V/PI cell staining in combination with flow 
cytometry in cells after exposure to AC (80 µM) for 10min up to 24h. Untreated cells in 
serum free medium is labeled as C(S-) in (A) and as C in (B). These values are presented 
as mean ± SD, (n=3); *p<0.001 is considered significant by one-way ANOVA using 
Dunnet’s post test.  
 
No significant changes in protein handling systems (Fig. 3.7 C and D) and cell 
viability (Fig. 3.9 A) were observed when cells were cultured in serum-free medium. In 
addition, no toxicity following AC treatment could be detected at early time points of 
10min, 30min and 2h as indicated by trypan blue exclusion assays or by flow cytometry 
analysis for apoptosis/necrosis (Fig. 3.9).  
MD exerted little influence on the ER stress response and autophagy  
Treatment with MD for 24h resulted in a dose-dependent cytotoxicity in N27 cells 
and a dose of 16µM of MD caused approximately 50% cell death (Fig. 3.10 A). The same 
time-course study used for BQ and AC was conducted to examine the effect of MD on 
the activities of major protein handling systems and its relationship to toxicity. MD had 
little effect on any protein handling systems including the expression of Hsp27, Hsp70 
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(not detectable) as well as Hsp90, the ER stress response and autophagy as indicated by 
p-elF2α and LC3 II (Fig. 3.10 B). No toxicity following MD treatment could be detected 
at the early time points of 10min, 30min and 2h as indicated by trypan blue exclusion 
assays or by flow cytometry analysis of apoptosis/necrosis (data not shown).  
 
Figure 3.10 MD exerted little influence on the ER stress response and autophagy. (A) 
Growth inhibition in N27 cells upon treatment with MD. Cells were incubated with 
increasing concentration of MD (0-80µM) for 24h and cell viability was assessed by the 
MTT assay. (B) Time course of the ER stress responses and autophagy following 
treatment with MD. Treatment with tunicamycin (Tn, 3µM) was included as positive 
control. β-actin was included as a loading control. Values in (A) are presented as mean ± 
SD, (n=3). 
Overexpression of NQO1 in N27 cells 
To better define the role of NQO1 in modulating quinone induced protein handling 
changes and toxicity, a stably transfected N27 cell line (clone 4) that expresses high 
levels of human wild type NQO1 protein was utilized. As shown in Figures 3.11 A and B 
parental N27 cells have low levels of NQO1 protein and acitivity (enzymatic activity of 
259nmol DCPIP/min/mg protein), whereas clone 4 cells expressed much higher levels of 
NQO1 (1022nmol DCPIP/min/mg protein). In clone 4 cells overexpression and cytosolic 




Figure 3.11 Overexpression of NQO1 in N27 cells (clone 4 cells) after stable transfection 
with wild type human NQO1. (A) NQO1 overexpression in clone 4 cells was confirmed 
by immunoblot analysis (rhNQO1, 35ng purified recombinant human NQO1 standard). 
(B) Cytosolic NQO1 enzymatic activity was measured in parental N27 and clone 4 cells 
as described in Materials and Methods. (C) Confocal analysis using immunostaining for 
NQO1 (red) in N27 cells (left) and clone 4 cells (right) confirmed cytosolic 
overexpression of NQO1 in clone 4 cells. Values in (B) are presented as mean ± SD, 
(n=3); ***p<0.001 are considered significant by student t-test. 
Modulation of quinone-induced ER stress response by NQO1 and its relationship to 
toxicity  
The mode of quinone toxicity was examined by flow cytometry using annexin V and 
PI double staining as markers for apoptosis. As shown in Figure 3.12, treatment with BQ 
resulted in significant levels of apoptosis at 24h with more than 40% of cells staining 
positive for annexin V (Fig. 3.12 A), while treatment with AC and MD induced apoptosis 
in about 30% of cells (Fig. 3.12 B and C). These results indicate that N27 cells were 
sensitive to apoptotic cell death after treatment with quinones for 24h. A significant 
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decrease in BQ induced apoptosis was detected at 24h in NQO1-overexpressing clone 4 
cells suggesting that clone 4 cells are more resistant to BQ toxicity (Fig. 3.12 A). In 
contrast, clone 4 cells were more sensitive to AC- and MD-induced toxicity as indicated 
by a significant increase in the percentage of apoptotic cells (Fig. 3.12 B and C). These 
data suggest that overexpression of NQO1 protected against BQ induced toxicity but 
potentiated AC and MD toxicity.  
To examine which protein handling system could be modulated by NQO1 and 
contributed to quinone toxicity, the activities of the major protein handling systems 
following treatment of N27 and clone 4 cells with quinones were compared. No 
significant differences in quinone induced proteasomal inhibition, autophagy and 
aggresome formation could be observed between N27 and clone 4 cells (data not shown). 
However, the data revealed that the ER stress response was tightly associated with 
quinone toxicity. In these studies caspase 12 was used as a marker for ER stress-mediated 
apoptosis as reported previously (80, 252) and as shown in Figure 6D, treatment of clone 
4 cells with BQ for 24h resulted in a decrease in p-eIF2α and caspase12 cleavage (C-
Caps 12) compared to N27 cells. In contrast, either AC or MD induced a further increase 
of p-eIF2α and cleaved caspase12 in clone 4 cells at 24h (Fig. 3.12 E and F). These data 
correlated with quinone-induced apoptosis in N27 and clone 4 cells (Fig. 3.12 A-C) 
suggesting that NQO1 modulated the ER stress response to potentiate toxicity of AC and 




Figure 3.12 Overexpression of NQO1 in N27 cells modulated the ER stress response to 
protect against BQ induced toxicity while potentiated toxicity induced by AC and MD. 
(A) Overexpression of NQO1 protected N27 cells against BQ induced apoptosis. (B, C) 
Clone 4 cells were more susceptible to AC (80µM) and MD (16µM) induced apoptosis. 
Apoptosis was measured in N27 and clone 4 cells after treatment with the indicated 
quinones for 24h using annexin V/PI cell staining in combination with flow cytometry. 
These data are presented as mean ± SD, (n=3); ***p< 0.001 are considered significant by 
one-way ANOVA using Tukey’s multiple comparison test. (D-F) Time course of the ER 
stress response and the ER stress mediated apoptosis pathway following treatment with 
BQ (20µM), AC (80µM) and MD (16µM). Note that cleaved caspase-12 (C-Caps 12) was 
activated indicating that quinones can induce ER stress mediated apoptosis. 
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NQO1 increased quinone induced oxidative stress that may contribute to the 
activation of the ER stress response and toxicity  
Since quinones are also capable of redox cycling and inducing oxidative stress, the 
role of NQO1 in modulation of quinone induced oxidative stress was examined. It is 
possible that NQO1 catalyzes two-electron reduction of quinones to unstable 
hydroquinones and subsequent redox cycling leads to increased oxidative stress and 
toxicity of AC and MD. To assess the relative stability of hydroquinones generated by 
NQO1 the rates of oxygen consumption were measured in N27 and clone 4 cells 
immediately after treatment with quinones. In both N27 and clone 4 cells the rate of 
oxygen consumption after treatment with BQ did not change significantly suggesting that 
hydroquinone does not undergo significant oxidation in these cells in the time period 
examined. In contrast, the rates of oxygen consumption following treatment with the 
equivalent dose of AC or MD were greater in clone 4 cells compared to parental N27 
cells (Fig. 3.13 A) indicating that reduction of AC and MD by NQO1 generates redox 
active metabolites (leukoaminochrome and menadiol). These data demonstrated that 
NQO1 increased the rates of redox cycling of AC and MD, which may in turn, led to 
increased levels of oxidative stress. 
To confirm that NQO1 contributed to the increased oxidative stress induced by 
quinones I combined immunostaining using anti-NQO1 antibody with the superoxide 
reactive  fluorescent  probe CellROX  Green
®





Figure 3.13 Overexpression of NQO1 increased AC and MD but not BQ, induced 
oxidative stress in clone 4 cells.      
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Figure 3.13 Overexpression of NQO1 increased AC and MD but not BQ, induced 
oxidative stress in clone 4 cells. (A) NQO1 overexpression increased the rate of oxygen 
consumption following treatments with AC or MD in N27 cells. Oxygen consumption 
was measured in N27 cells and clone 4 cells in the absence (control) or presence of the 
indicated quinones. Measurements were made over 10min using a Clark electrode at 
37°C. Overexpression of NQO1 in clone 4 cells resulted in significantly increased 
oxygen consumption after treatment with either AC or MD suggesting unstable 
hydroquinones of AC or MD were generated and undergo autoxidation. These data are 
presented as mean ± SD, (n=3); *p<0.05 and ***p<0.001 are considered significant by 
one-way ANOVA using Tukey’s post test, # p<0.05 is significant comparing to untreated 
control. (B) Quinone-induced oxidative stress was measured using CellROX Green
®
 
reagent in combination with confocal microscopy. Note the intense green staining in the 
nucleus of clone 4 cells compared to N27 cells after treatment with AC and MD 


















other oxidants, CellROX Green forms a relatively photostable green fluorescent product 
that is stable after fixation with formaldehyde and suitable for confocal microscopy. 
Green fluorescent staining is normally observed in the nucleus because CellROX Green 
can move into the nucleus and intercalate into DNA. As show in Figure 3.13 B(a), no 
green fluorescence was observed in the absence of quinone treatment in both N27 and 
clone 4 cells. In addition, treatment of N27 or clone 4 cells with BQ (20µM) did not 
result in green fluorescent staining confirming that BQ did not induce significant 
oxidative stress in either N27 or clone 4 cells (Fig. 3.13 B-b). However, treatment with 
AC (80µM) or MD (16µM) resulted in intense green fluorescence in the nucleus of both 
N27 and clone 4 cells indicating that oxidative stress was induced by these quinones (Fig. 
3.13 B-c,d). Moreover, the green fluorescent staining was greater in the nucleus of clone 
4 cells following treatment with AC and MD further confirming a role of NQO1 in the 
production of redox active metabolites (Fig. 3.13 B-c,d). In agreement with the oxygen 
consumption data these results demonstrated that NQO1 potentiated quinone induced 
oxidative stress that may contribute to the increased activation of the ER stress response 
and subsequent toxicity in clone 4 cells (Fig. 3.12).  
Discussion 
In the present study, three representative quinones including the dopamine oxidation 
product AC, the environmentally relevant quinones BQ and vitamin K analog MD were 
compared to define the role of protein handling systems in quinone-mediated toxicity. 
Although AC has previously been shown to inhibit proteasomal activity in rabbit 
reticulocyte lysates (12) and dopaminergic neuronal MN9D cell extracts (219, 245), 
results this study demonstrated for the first time that AC and BQ were capable of 
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proteasomal inhibition using the purified human 20S proteasome. Despite the fact that the 
26S proteasome exhibits different enzymatic activities, it still requires the 20S 
proteasome core to function and current small molecule inhibitors are designed only for 
the catalytic sites of the 20S proteasome (40).  Therefore, the effect of quinones on 
proteasomal activity was examined using the purified 20S proteasome in this thesis. 
Quinone-induced proteasomal inhibition was further confirmed using rat dopaminergic 
N27 cells. 
Chemically, AC, BQ and MD are all capable of both redox cycling and arylation. To 
discriminate whether quinone-induced proteasomal inhibition was induced by ROS 
production or arylation, DQ the fully substituted quinone analog of BQ was used. 
Substituted analogs of AC were not synthetically accessible and MD itself did not inhibit 
the proteasome so the analysis was restricted to BQ. Exposure to DQ did not result in 
inhibition of 20S proteasomal activity suggesting a major role of arylation in BQ-induced 
proteasomal inhibition. The observed proteasomal inhibition by AC or BQ might be due 
to arylation reactions with cysteine or lysine residues critical for peptidase activities of 
the proteasome as suggested by previous studies (49-51, 57, 253). It is also possible that 
the activities of other peptidase sites could be allosterically stimulated or inhibited by 
quinones acting on non-catalytic regulatory sites (49-51). Interestingly, AC induced the 
most pronounced changes in the number of major protein handling systems affected. 
Conversely, MD had little effect on major protein handling systems.  
Arylating quinones, such as BQ, have been shown to induce ER stress by activating 
the p-elF2α signaling pathway (14). Although the underlying mechanism remains 
unclear, it has been proposed that Michael adducts formed by quinones with ER protein 
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disulfide isomerases (21) disrupt the formation of disulfide bonds in the ER and thus 
cause accumulation of misfolded proteins and ER stress. Results obtained using BQ in 
this study suggest an additional possible explanation for a quinone-triggered ER stress 
response. BQ was found to induce early proteasomal inhibition that was tightly 
associated with the rapid activation of the ER stress response in N27 cells. Since the ER 
stress response can be triggered by impairment of the UPS (126, 235, 246) it is likely 
activated as a cellular defense mechanism. However, further aggravation of ER stress will 
trigger apoptosis. The ER stress response could be modulated by NQO1 which resulted in 
potentiation of the toxicity of AC and MD, or alternatively protection against BQ 
toxicity.  
A neuroprotective role of NQO1 in AC toxicity has been proposed recently (16). This 
work used a cell model in which both vesicular monoamine transporter-2 (VMAT-2) and 
NQO1 were overexpressed. A lack of evidence using a NQO1 single-overexpression 
model makes it difficult to define the role of NQO1 alone in AC-mediated neurotoxicity. 
Therefore, the isogenic NQO1-overexpressing neuronal cell line was used in the current 
study to better characterize AC induced changes, particularly with respect to protein 
handling, and further examined whether NQO1 modulated these changes and toxicity 
induced by AC. In contrast with the study of Munoz et al. using a catecholaminergic 
RCSN-3 cell line, results in this study demonstrated that metabolism by NQO1 did not 
result in the detoxification of AC at least in N27 cells. The data indicated that NQO1 
mediated reduction of AC to an unstable hydroquinone and subsequent redox cycling was 
associated with activation of the ER stress response and subsequent toxicity. Although 
the potential importance of NQO1 in the modulation of redox cycling of 
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leukoaminochrome (the hydroquinone form of AC) has been discussed previously (254), 
the work in this thesis demonstrated for the first time that NQO1 mediated redox cycling 
of aminochrome/leukoaminochrome contributed to AC-induced toxicity. Since NQO1 
was also found to increase the redox cycling and toxicity of MD, but not BQ, it appears 
that the reduction potential of a specific quinone/hydroquinone couple is tightly 
associated with the role of NQO1 in quinone-mediated toxicity.  
Consistent with previous studies (16, 34), the data demonstrated that AC could 
activate autophagy. More intriguingly, ubiquitin positive aggresome-like inclusion bodies 
were also detected in AC treated cells. Given autophagy and aggresome formation have 
been suggested as compensatory responses after proteasomal inhibition (72, 73, 246), and 
the potential importance of proteasomal inhibition in the biogenesis of protein aggregates 
in Parkinson’s disease (29, 131-133), the findings in the current study may provide a 
better understanding of accumulation of protein aggregates in Parkinson’s disease 
associated with dopamine induced proteasomal inhibition. 
In summary, the results have demonstrated (Fig. 8) that the nature and extent of 
protein handling changes was quinone-specific. AC induced changes in most of the major 
protein handling systems examined including proteasomal activity, the ER stress 
response, autophagy and formation of aggresome-like inclusion bodies. Both BQ and AC 
induced proteasomal inhibition that was closely associated temporally with induction of 
the ER stress response and autophagy. The effect of NQO1 on modulating protein 
handling changes and toxicity was also quinone-specific. While two-electron reduction of 
BQ protected against toxicity, the unstable hydroquinones generated from AC and MD 
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underwent rapid autoxidation to produce ROS leading to an activated ER stress response 
and increased toxicity. 
 
















A NOVEL HSP90 INHIBITOR ACTIVATES COMPENSATORY HEAT SHOCK 




Hsp90 is a crucial molecular chaperone that functions to correctly fold client 
protein， thereby preventing them from degradation by the ubiquitin-proteasome system 
(UPS) (255). More than 200 client proteins of Hsp90 have been identified including a 
range of prosurvival proteins (also known as oncoproteins) such as Raf-1, Akt, p53 and 
cdk4 (256) as well as neural proteins including polyglutamine-expanded mutant androgen 
receptor (257) and leucine-rich repeat kinase 2 (LRRK2) (258).  
One of the major causes of neurodegenerative diseases including Parkinson’s Disease 
(PD) is the accumulation of misfolded protein aggregates that in turn leads to toxicity and 
loss of neurons (127, 259). In the brain, α-synuclein (α-Syn) is highly abundant and plays 
a key role in the modulation of synaptic activity. α-Syn is also the main component of 
Lewy bodies (LW) and Lewy neurites (LN) in the PD brain, and mutations in the gene 
encoding α-Syn (SNCA gene) have been implicated in the early onset of familial forms 
of PD (260). A53T α-Syn is one of the mutant forms of α-Syn that has been intensively 
studied. Despite accumulating evidence for mutant A53T α-Syn in the pathogenesis of 
PD its role has not been fully elucidated. However, it is believed that the toxicity of A53T 
α-Syn is associated with formation of pre-fibrillar α-Syn oligomers (261).  
Recent studies suggest that inhibition of Hsp90 could be beneficial for 
neurodegenerative diseases (257, 262-264). Pharmacologic inhibition of Hsp90 has been 
3
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shown to be useful in neurodegenerative disease models (265, 266). There are at least 
three potential protective mechanisms associated with inhibition of Hsp90; 1) Hsp90 
inhibition leads to activation of heat shock factor 1 (Hsf-1) that further induces a range of 
small heat shock proteins (including Hsp70 and Hsp27) which assist in appropriate 
folding of misfolded proteins (267); 2) Inhibition of Hsp90 leads to the degradation of 
mutant neuronal client proteins such as polyglutamine-expanded mutant AR and LRRK2 
which reduces the load of toxic Hsp90 client proteins (257, 262, 263, 268) and (3) Hsp90 
inhibitors including 17-AAG have been shown to induce protective autophagy that led to 
degradation of mutant and misfolded protein aggregates (269). The benzoquinone 
ansamycin (BQA) Hsp90 inhibitors GA, 17-AAG and 17-DMAG have been shown to 
induce a robust compensatory heat shock response, and amelioration of protein 
aggregation and toxicity. Specifically with respect to PD, either GA or 17-AAG can 
inhibit α-synuclein aggregation and toxicity in cell, fly and yeast models (257, 262, 263, 
270).  
However, current BQAs inhibitors were relatively hepatotoxic in animal models and 
their off-target toxicities were mediated via redox cycling and arylation of nucleophiles at 
the C19 position of the benzoquinone ring (256, 271, 272). In collaboration with 
Professor Christopher J. Moody, novel 19-substituted BQA (19BQA) Hsp90 inhibitors 
have been developed as a means to prevent arylation. Earlier results by our lab have 
validated this approach by using model thiols (273, 274). This study was designed to 
evaluate the use of novel 19BQAs as potential therapeutic agents for PD. A transient 
A53T α-Syn overexpression model was established and 19-Ph-GA was used as proof of 
principle that i) 19BQAs had reduced toxicity relative to GA in SH-SY5Y cells and ii) 
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were able to induce compensatory changes in protein handling to ameliorate A53T α-Syn 
oligomer formation and toxicity.  
Materials and methods 
Materials and antibodies  
17-AAG and GA were purchased from LC Laboratories (Woburn, MA); 19-phenyl-
GA-(19-Ph-GA), 19-methyl-GA (19-Me-GA), 19-(4-phenyl-phenyl)-GA (19-Ph-Ph-GA), 
19-(4-morpholinyl-phenyl)-GA (19-Ph-Mor-GA), 19-(4-methoxy-phenyl)-GA (19-Ph-
OMe-GA), 19-dimethylamino-GA (19-DMA-GA), 19-hydroxymethyl-GA (19-HM-GA) 
were synthesized in the lab of Professor Christopher J. Moody (University of 
Nottingham, UK) as described previously (274, 275). NADH, DAPI, chloroquine 
diphosphate, ATP disodium salt, digitonin, phenylmethylsulfonyl fluoride (PMSF), 
bovine serum albumin and mouse monoclonal anti-β-actin (A5441) antibody were 
obtained from Sigma Chemical (St. Louis, MO, USA). Dithiothreitol was purchased from 
Fisher Scientific (Pittsburgh, PA, USA). MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-tetrazolium bromide] was obtained from Research Products International 
(Mount Prospect, IL, USA). Mouse anti-α-synuclein (610786) antibody was from BD 
transduction laboratories (San Jose, CA, USA). Mouse monoclonal anti-Hsp27 (ADI-
SPA-800), anti-Hsp70 (ADI-SPA-810) antibodies and rabbit polyclonal anti-p62 (BML-
PW9860) antibody were purchased from Enzo (Farmingdale, NY, USA). FITC / annexin 
V (640906) and annexin V binding buffer (422201) were purchased from BioLegend 
(San Diego, CA, USA). The proteasome substrate Suc-Leu-Leu-Val-Tyr-AMC was 
purchased from Bachem (Torrance, CA, USA). Rabbit polyclonal anti-LC3 (NB100-2331 
and NB600-1384) antibody was from Novus (Littleton, CO, USA). Rabbit polyclonal 
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anti-phospho-mTOR (Ser2448, #2971), anti-mTOR (#2972), anti-phospho-P70S6K 
(Thr389, #9205), anti-P70S6K (#9202), anti-phospho-eIF2α (Ser51, #9721) and anti-
eIF2α (#9722) antibodies were purchased from Cell Signaling Technology (Danvers, 
MA, USA).  
Cell culture and treatment 
SH-SY5Y cells were purchased from American Type Culture Collection (Manassas, 
VA).  Cells were cultured in DMEM/F-12 medium (Cellgro, Manassas, VA, USA) 
containing 10% (v/v) fetal bovine serum, 2mM glutamine (ATCC, Manassas, VA, USA) 
100 units/ml penicillin and 100 µg/ml streptomycin (Cellgro, Manassas, VA, USA) in a 
humidified atmosphere of 5% CO2 at 37°C.  
Adenoviral transient transduction  
Adenoviruses (kindly provided by Dr. Wenbo Zhou and Dr. Curt Freed) expressing 
either A53T mutated α-synuclein (A53T α-Syn), wild-type α-synuclein (WT α-Syn) or 
green fluorescent protein (GFP) were constructed and produced in two-step Ad-Easy 
systems (276). Adenoviruses were mixed with culture medium and incubated with cells 
at a concentration of 100 to 400 plaque forming units (pfu)/cell as described previously 
(276, 277).  
MTT growth inhibition assay  
Drug induced toxicity was determined using the MTT assay. SH-SY5Y cells were 
seeded at 5000 cells per well in 96-well plates or 40000 cells per well in 48-well plates 
(in triplicate). After 24h the cells were incubated with adenoviruses expressing either 
A53T mutated α-synuclein (A53T α-Syn) or wild-type α-synuclein (WT α-Syn) in 
complete medium in 48-well plates. One day after adenovirus transduction cells were 
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exposed to 19BQAs at varying concentrations for 48h after which, the medium were 
removed and replaced with complete medium containing MTT (0.4mg/ml). The MTT 
containing medium was removed after 2h incubation and the MTT formazan product was 
extracted from cells with 200µl of dimethyl sulfoxide. The optical density of the extract 
was determined at 550nm with a microplate reader. IC50 values were defined as the 
concentration of drugs that resulted in a 50% reduction in cell density compared to 
DMSO treated controls. 
Trypan blue exclusion assay  
Cells were seeded at 0.5 × 10
6
 cells into 60 mm × 15 mm tissue culture dishes in 3 ml 
of complete medium and allowed to grow for 24h. Following treatment with the indicated 
compound for 24h, cell pellets containing both floating and attached cells were collected 
and then resuspended in 1ml PBS. To assess cell viability the cell suspension (10 µl) was 
stained with 10 µl trypan blue dye (0.4% w/v in PBS). The number of viable cells was 
determined using a Life Technologies CountessTM automated cell counter immediately 
after staining.  
Apoptosis assay  
Apoptosis was determined by flow cytometry using FITC-conjugated anti-annexin V 
and propidium iodide (PI) as previously described (246).After the indicated treatments, 
cell pellets including both the floating and attached cells were collected and resuspended 
in 500 µl of annexin V binding buffer and incubated with anti-annexin V antibody (2 µl) 
and PI (0.7 µl of 100 µg/ml stock) for 10 min at 37°C in the dark. Samples were kept on 
ice, and then analyzed using a BD Biosciences FACS Calibur Flow Cytometer (San Jose, 
CA, USA). The fluorescence was measured at 530nm (FL1, FITC) and PI at above 
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600nm (FL2), and the data was acquired and analyzed using Cellquest software (Becton-
Dickenson, Mountainview, CA, USA). 
Proteasomal activity assay 
Proteasomal activity was determined by measuring the fluorescence of cleaved 
proteasome substrate Suc-Leu-Leu-Val-Tyr-AMC (chymotrypsin-like activity) as 
described previously (226, 246, 278). Briefly, after the indicated treatments, the medium 
was removed and the cells were washed with PBS (3ml) three times, and then lysed with 
proteasomal activity assay buffer and centrifuged at 10,000g for 14min at 4°C. The 
supernatants were collected and protein concentrations were determined using the method 
of Lowry (227). To assay proteasome activity cell lysate (20µg) was added to 100µl of 
proteasome activity assay buffer (50mM Tris–HCl, pH 7.5, 250mM sucrose, 1mM 
dithiothreitol, 5mM MgCl2, 2mM ATP, 0.5mM EDTA and 0.025% (w/v) digitonin) 
followed by the addition of 100µM proteasome substrate Suc-Leu-Leu-Val-Tyr-AMC. 
After incubation at 37°C for 30 min, 40µl samples were transferred to a 96-well plate and 
the fluorescence of liberated 7-amino-4-methylcoumarin (Ex: 380nm; Em: 460nm) was 
measured in duplicate samples. 
Immunoblot analysis 
Cells were seeded at 400,000 cells per well in 6-well plate. Following the indicated 
treatments cells were washed with PBS and then attached cells were collected and lysed 
with RIPA buffer (50mM Tris-HCl, pH 7.4, 150mM NaCl, 0.1% (w/v) SDS, 1% (v/v) 
NP-40, 0.5% (w/v) sodium deoxycholate) supplemented with protease inhibitors 
(Complete, Mini Protease Inhibitor Cocktail, Roche, Germany), PMSF (2mM) and 
phosphatase inhibitors (Sigma Chemical, USA). Cells were sonicated on ice and then 
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centrifuged at 10,000g for 14 min at 4°C. The supernatants were collected and protein 
concentrations were measured using the method of Lowry (227). Proteins were diluted in 
2X Laemmli SDS sample buffer and heated to 70°C for 5 min, and then separated on a 
12% SDS-PAGE precast minigel (BioRad Laboratories, Hercules, CA, USA). A 7.5% 
SDS-PAGE precast minigel was used to separate the high molecular weight oligomers. 
Proteins were transferred to polyvinylidene fluoride membranes in 25mM Tris, 192mM 
glycine containing 20% (v/v) methanol at 4°C. Membranes were incubated in blocking 
buffer (10mM Tris-HCl, pH 8.0, 150mM NaCl, 0.2% (v/v) Tween-20 (TBST) containing 
5% (w/v) non-fat dry milk) for 1h, and then incubated with primary antibodies overnight 
at 4°C. Membranes were washed every 10min in TBST for 1h and then probed with 
horseradish peroxidase-conjugated goat anti-rabbit or horseradish peroxidase-conjugated 
goat anti-mouse IgG (1:5000; Jackson Immunoresearch Labs, West Grove, PA, USA) for 
30min at room temperature. Membranes were washed three times in TBST and protein 
bands were visualized using enhanced chemiluminescence (Thermo Scientific, USA). 
Adobe Photoshop CS6 was used to quantitate immunoblots from three independent 
experiments.  
Oxygen consumption assay 
The ability of 19BQAs to undergo redox cycling in SH-SY5Y cells was determined 
using an airtight Clark electrode (Yellow Springs Instrument Company, Yellow Springs 
OH, USA). For these studies 5 million cells were suspended in 3ml of complete cell 
culture medium at 37°C in the presence or absence of compounds and the rate of oxygen 
consumption was measured over 10min Dissolved oxygen concentrations were adjusted 
for altitude (5280 feet) and temperature (37°C).  
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Statistical analysis 
All experiments were repeated at least three times, and the values were expressed as 
means ± standard deviation (SD). The statistical significance was determined using Prism 
6.0 software (GraphPad Software, San Diego, CA). One-way analysis of variance 
(ANOVA) followed by the Tukey or Dunnet’s multiple comparison tests was used.  
Results 
Decreased toxicity of 19BQAs relative to their parent quinone geldanamycin (GA) 
in SH-SY5Y cells 
More than 20 compounds were synthesized with different substituents at the C19 
position of GA, 17-AAG and 17-DMAG. 19BQAs in the GA series were examined in 
this study (Fig. 4.1) while the structure information and biological data of 19BQAs in the 
17-AAG and 17-DMAG series are listed in Appendix. The potential toxicity of 19BQAs 
was first examined in human dopaminergic SH-SY5Y (5Y) cells using a short term MTT 
test as an initial screen. As shown in Figure 4.2 A, GA induced a significant loss in cell 
viability at low concentration (IC50 293nM), compared to 19-Ph-GA (IC50 >10µM). In 
addition, 19BQAs were also less toxic than 17-DMAG (IC50 6.8µM). Overall, these 
results using this initial screen indicated that 19BQAs induced substantially decreased 
toxicity relative to GA and 17-DMAG.  
The relatively low toxicity of 19-Ph-GA was then confirmed using the trypan blue 
exclusion assay and flow cytometry using annexin V and propidium iodide (PI) double 
staining for apoptosis. As shown in Figure 4.1 B and C, no significant toxicity could be 
detected following treatment with 19-Ph-GA (250nM) for 24h while exposure to GA at 
the equivalent dose resulted in over 30% of cell death and significant morphological 
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changes in 5Y cells. Significant induction of apoptosis (Fig. 4.1 D) was also observed 
after 24h treatment with a higher dose (5 µM) of GA while exposure to 19-Ph-GA (5 µM) 
did not increase numbers of apoptotic cells.         
 
Figure 4.1 Chemical structures of benzoquinone ansamycin (BQA). Substitutions at the 
19-position (R) include phenyl (Ph), 4-phenyl-phenyl (Ph-Ph), naphthyl, 4-methoxy-
phenyl (Ph-OMe), 4-morpholinyl-phenyl (Ph-Mor), hydroxymethyl (HM), 




Figure 4.2 19BQAs exerted decreased toxicity compared with their parent quinone GA. 
(A) Growth inhibition induced by 19BQAs in 5Y cells. Growth inhibition was measured 
using the MTT assay. Cells were treated with BQAs for 4hr then allowed to grow for an 
additional 72hr. (B) Cells were treated with GA and 19-Ph-GA at 0.25 µM for 24h and 
harvested for determination of cell number by using a trypan blue exclusion assay. (C) 
Morphological changes of 5Y cells following treatment with GA and 19-Ph-GA. Bright 
field microscope images showed that treatment of 5Y cells with GA at 0.25 µM for 24h 
resulted in lost of cell neurites (black arrows) while exposure to 19-Ph-GA at the 
equivalent dose did not affect the morphology of cells. (D) Apoptosis was measured 
using annexin V/PI cell staining in combination with flow cytometry in cells after 
exposure to the equivalent dose (5 µM) of GA or 19-Ph-GA for 16h. (E) Oxygen 
consumption was measured in cells in the absence (basal) or presence of the indicated 
compounds. Measurements were made over 10min using a Clark electrode at 37°C. 
Menadione was included as a redox-cycling quinone (positive control). These values are 
expressed as the mean ± SD, n=3. *p<0.05, ***p<0.001 is considered significantly 
different from basal by one-way ANOVA using Dunnet’s multiple comparison test. 
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19-substitution prevents the ability of BQAs to induce toxicity via arylation of 
cellular nucleophiles (273). An additional concern with quinone based drugs is their 
ability to undergo redox cycling and generate reactive oxygen species (ROS) which in 
turn results in off-target toxicities. To determine whether 19BQAs undergo appreciable 
redox cycling, the rates of oxygen consumption in 5Y cells were measured in the absence 
and presence of GA or 19-Ph-GA. Results from these studies demonstrated that exposure 
to 19-Ph-GA at a relatively high dose (10 µM) did not significantly increase the rate of 
oxygen consumption in contrast to exposure to GA which resulted in two-fold increases 
in the rates of oxygen consumption (Fig. 4.2 E). These results demonstrated that 19BQAs 
such as 19-Ph-GA were less redox active and had significantly decreased toxicity relative 
to GA in 5Y cells. 
19BQAs are potent inducers of heat shock proteins 
Earlier results by our lab have demonstrated that 19BQAs inhibit Hsp90 ATPase 
activity and induce cytotoxicity in human cancer cells (273). The experiments were 
performed to examine the efficacy of 19BQAs as Hsp90 inhibitors in dopaminergic 5Y 
cells. Screening was carried out at nanomolar doses (250-500nM) for 16h and results 
from these experiments (Fig. 4.3) clearly show that many 19BQAs including 19-Ph-GA 
are potent inducers of HSPs. At these low doses examined of 19-Ph-GA, significant 
degradation of prosurvival kinases  (p-Akt, Raf-1) did not occur but treatment with higher 
doses (5-10 µM) of 19-Ph-GA resulted in apparent degradation of p-Akt and Raf-1 (data 
not shown). These results also demonstrate that many 19-substituted GA analogs, 
although not all, are comparable or superior to the clinically tested Hsp90 inhibitor 17-
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AAG in their ability to induce protective HSPs in 5Y cells. The subsequent studies were 
focused on 19-Ph-GA to demonstrate proof of principle. 
 
Figure 4.3 Treatment with 19BQAs induced HSPs in 5Y cells. Immunblot analysis of 
biomarkers of Hsp90 inhibition following treatment with BQAs at the indicated 
concentrations for 16h. Note that many 19BQAs induced potent expression of Hsp70 and 
Hsp27. 
Overexpression of A53T α-synuclein (α-Syn) resulted in protein handling changes 
and toxicity 
Adenoviral transduction of 5Y cells with mutant A53T α-synuclein (A53T α-Syn) 
was utilized as a cellular model for PD. Interestingly, the overexpression of A53T α-Syn 
perturbed several key protein handling systems that have been previously shown to be 
important for determining the fate of misfolded or aggregated proteins (246, 267, 279). 
As shown in Figure 4.4A, increased expression of A53T, but not WT, α-Syn led to 
significant dose dependent growth inhibition of 5Y cells and these data correlated with 
decreased proteasome activity  (Fig. 4.4 B) suggesting that impaired proteasome function 
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may be associated with A53T α-Syn toxicity as previously reported in PC12 cells (280). 
In addition to the ubiquitin proteasome system (UPS), the autophagy-lysosome pathway 
(ALP), molecular chaperones and the ER stress response/unfolded protein response 
(UPR) all work in concert to maintain intracellular protein homeostasis (246, 259, 278). 
In these studies, overexpression of A53T α-Syn induced the ER stress response and 
autophagy in 5Y cells as indicated by the sustained increase in the ER stress marker p-
eIF2α and the autophagy marker LC3 II (Fig. 4.4 C). In addition, enhanced degradation 
of the autophagy substrate p62 (Fig. 4.4 C) was also observed following transduction 
with A53T α-Syn. To further examine the effect of A53T α-Syn expression on 
autophagy, 5Y cells (previously transduced with A53T α-Syn for 24h) were treated with 
chloroquine (CQ) for an additional 48h. CQ is a lysosome inhibitor and suppresses the 
fusion of autophagosomes with lysosomes and blocks autophagic degradation. The levels 
of LC3 II further increased after CQ treatment excluding the possibility that A53T α-Syn 
stimulated autophagic flux was due to the blockade of autophagic degradation (Fig. 4.4 
D). These results demonstrated that autophagy was activated by increased A53T α-Syn 
expression in 5Y cells. Surprisingly, expression of the protective chaperones Hsp70 and 
Hsp27 was slightly reduced after elevated expression of A53T α-Syn in 5Y cells (Fig. 4.4 





Figure 4.4 Overexpression of human mutant A53T α-Syn induced protein handling 






Figure 4.4 Overexpression of human mutant A53T α-Syn induced protein handling 
changes and toxicity in 5Y cells. (A) One day after seeding, cells were transduced with 
mutant A53T α-Syn (MOI from 100 to 800 pfu/cell) and WT α-Syn (MOI 400 pfu/cell) 
for 72h. Cell viability was then determined by the MTT assay. (B) Overexpression of 
A53T α-Syn inhibited intracellular 20/26S proteasomal activity (chymotrypsin-like active 
site) in a dose-dependent manner. (C) Hsp70 and Hsp27 protein levels and induction of 
the ER stress response and autophagy following transduction with A53T α-Syn. (D) 
Autophagy induction in A53T α-Syn overexpressing cells was confirmed by co-treatment 
with chloroquine (CQ, 40µM). 5Y cells were transduced with adenovirus expressing 
mutant A53T α-Syn at an MOI of 200 or 400 pfu/cell for 24h followed by incubation 
with or without CQ for 48h and then processed for immunoblot analysis. (E-F) MOI-
dependent increase in HMW α-Syn oligomers was detected 72h after transduction with 
A53T α-Syn but not WT α-Syn and GFP adenovirus vector control (MOI 400 pfu/cell). 
(G) The combined treatment of A53T α-Syn (MOI 400 pfu/cell) with CQ (40µM) 
resulted in the accumulation of higher levels of α-Syn oligomers suggesting autophagy 
was important for α-syn oligomers degradation in 5Y cells. β-actin was included as a 
loading control. Values in (A) and (B) are presented as mean ± SD, (n=3); *p<0.05 is 











Notably, overexpression of mutant A53T but not WT α-Syn or GFP vector control 
induced the formation of high molecular weight α-Syn (HMW α-Syn) oligomers in 5Y 
cells (Fig. 4.4 E and F). Since the transduction with WT α-Syn did not result in 
significant toxicity (Fig. 4.4 A), these data are consistent with previous literature (261, 
281) suggesting a link between A53T α-Syn oligomer formation and toxicity in 5Y cells. 
It is also noteworthy that treatment with the lysosome inhibitor CQ resulted in a greater 
level of α-Syn oligomers in 5Y cells indicating that autophagy may be an important 
protective mechanism for α-Syn oligomer degradation (Fig. 4.4 G).  
19-Ph-GA alleviated A53T α-Syn induced toxicity 
Continuous exposure (72h) of 5Y cells to 19-Ph-GA at a concentration of 2.5 µM 
resulted in a small but significant loss of cell viability while treatment with higher doses 
showed increased toxicity. Lower doses (0.5-1 µM) of 19-Ph-GA were nontoxic (Fig. 4.5 
A). Importantly, 19-Ph-GA was able to significantly alleviate A53T α-Syn induced 
toxicity. As shown in Figure 4.5 B, after 48h treatment with non toxic doses of 19-Ph-GA 
(0.5-1 µM), the viability of A53T α-Syn overexpressing cells was increased over 20% 
and was not significantly different from untreated cells. In addition, after 48h post-
treatment with either 17-AAG or 17-DMAG at the equivalent dose (0.5-1 µM) significant 
cell death was observed and there was no beneficial effect on A53T α-Syn toxicity (Fig. 
4.5 C). Pretreatment and co-treatment with 19-Ph-GA, relative to A53T α-Syn 
transduction were also tested but neither was as effective as post-treatment in terms of 
improving cell viability (Fig. 4.6). These results demonstrated that exposure to low doses 
of 19-Ph-GA were beneficial and ameliorated A53T α-Syn induced toxicity in 5Y cells.  
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Figure 4.5 Post-treatment with 19-Ph-GA for 48h significantly attenuated A53T α-Syn 
induced toxicity in 5Y cells. (A) Treatment with low doses of 19-Ph-GA (0.5-1 µM) for 
72h was not cytotoxic to 5Y cells. (B) After 24h incubation with adenovirus expressing 
mutant A53T α-Syn (400 pfu/cell), cells were exposed to the indicated doses of 19-Ph-
GA for 48h after which cell viability was determined by the MTT assay. Triplicate 
treatments in 48-well plates were used. Results represent one experiment typical of n=5. 
Values are presented as mean ± SD, (n=3); *p<0.05, **p<0.01 is considered significant 
compared with control in (A) and relative to A53T α-Syn group in (B), respectively, by 
one-way ANOVA using a Tukey’s multiple comparison test. (C) After 24h incubation 
with adenovirus expressing mutant A53T α-Syn (400 pfu/cell), cells were exposed to the 
indicated doses of 19-Ph-GA, 17-AAG or 17-DMAG for 48h. Note that significant cell 
death was observed after 48h post-treatment with either 17-AAG or 17-DMAG at the 
equivalent dose (0.5-1 µM) of 19-Ph-GA and there was no beneficial effect on A53T α-
Syn toxicity. Cell viability was determined by the MTT assay. Values are presented as 
mean ± SD, (n=3); *p<0.05, ***p<0.001 is considered significant relative to control 
group; #p<0.05 is considered significant compared with A53T α-Syn group by one-way 
ANOVA using a Tukey’s multiple comparison test.  
 98 
 
Figure 4.6 Pretreatment or co-treatment with 19-Ph-GA was not able to alleviate A53T α-
Syn induced toxicity in 5Y cells. (A) Cells were pre-treated with 19-Ph-GA at the 
indicated doses for 16h and incubated with adenovirus expressing mutant A53T α-Syn 
(400 pfu/cell) for 72h. Cell viability was determined by the MTT assay. (B) Cells were 
incubated with adenovirus expressing mutant A53T α-Syn (400 pfu/cell) and 19-Ph-GA 
at the indicated doses for 72h after which cell viability was determined by the MTT 
assay. Triplicate treatments in 48-well plates were used. These values are presented as 
mean ± SD, (n=3); No significant (NS) changes compared with A53T α-Syn group by 
one-way ANOVA using a Tukey’s multiple comparison test. 
19-Ph-GA activated HSP response and autophagy that may contribute to the 
decreased oligomer formation and toxicity of A53T α-Syn 
 To further examine potential mechanisms underlying 19-Ph-GA mediated protective 
effects, biochemical changes modulated by 19-Ph-GA particularly with respect to protein 
handling systems were characterized. As shown in Figure 4.7 A and B, after 24h 
transduction with A53T α-Syn, exposure of 5Y cells to 19-Ph-GA for 48h resulted in a 
significant decrease in HMW α-Syn oligomers while α-Syn monomers were not 




oligomers. Interestingly, in these studies treatment with 19-Ph-GA led to a decrease in 
native HMW α-Syn oligomers as well as some redistribution of HMW α-Syn oligomers 
to smaller oligomers (~76kD) (Fig. 4.7 C). It is likely that 19-Ph-GA mediated its 
protective effects via induction of Hsp70 and Hsp27 to refold mutant A53T α-Syn and 
prevented higher molecular weight oligomer formation in addition to stimulation of 
autophagy causing oligomer degradation. However, only the concomitant induction of 
Hsp70 and Hsp27 but not induction of LC3 II was observed by the end of 48h treatment 
with 19-Ph-GA (Fig. 4.7 D).  
To further examine potential alterations of autophagic flux induced by 19-Ph-GA, a 
time-course study was conducted and the results showed that 19-Ph-GA was able to 
stimulate a temporal autophagic flux particularly during the early phase (up to 24h) of 
drug treatment (Fig. 4.7 E and F). Since 19-Ph-GA did not modulate the ER stress 
response as indicated by the expression of p-eIF2α (Fig. 4.7 D) and had little effect on 
A53T α-Syn induced proteasomal inhibition (Fig. 4.8), the temporal autophagy activated 
by 19-Ph-GA might be particularly important as an alternative pathway for α-Syn 
oligomer degradation. Thus, these results suggest that both the ability of 19-Ph-GA to 
induce HSP expression as well as to activate autophagy should be considered as potential 
mechanisms for decreasing A53T α-Syn oligomer formation and toxicity in 5Y cells. 
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Figure 4.7 19-Ph-GA significantly reduced A53T α-Syn oligomer formation through 














Figure 4.7 19-Ph-GA significantly reduced A53T α-Syn oligomer formation through 
induction of HSP responses and autophagy (A, B) α-Syn oligomers (denatured) were 
significantly reduced after 48h post-treatment of 5Y cells with 19-Ph-GA. (B) Fold 
changes of α-Syn oligomers in (A) after the drug treatment are normalized to respective 
controls and estimated by densitometry.  (C) Exposure of 5Y cells to 19-Ph-GA resulted 
in decreased levels of native high molecular weight α-Syn oligomers as well as an 
increase in the smaller (76 kDa) oligomer species. (D) After 48h post-treatment with 19-
Ph-GA, Hsp70 and Hsp27 protein levels were elevated 2- to 3-fold but biomarkers of 
autophagy and ER stress were not significantly perturbed. (E) Time-course study showed 
that 19-Ph-GA was able to upregulate both HSPs and LC3 II expression in 5Y cells. Note 
that exposure to 19-Ph-GA for 24h induced the maximum increase in LC3 II suggesting 
19-Ph-GA stimulated a temporal autophagic flux in 5Y cells. (F, G) Significant induction 
of HSPs and LC3 II could be detected in A53T α-Syn overexpressing cells after post-
treatment with 19-Ph-GA (0.5 µM) for 24h suggesting that HSP response and autophagic 
flux were stimulated by 19-Ph-GA at relatively early time points. β-actin was included as 
a loading control. Representative blot from three repeated experiments was showed for 
each figure. (G) Fold changes of Hsp70, Hsp27 and LC3 II in (F) after the drug treatment 
at the indicated times are normalized to respective controls and estimated by 
densitometry. Values in (B) and (G) are presented as mean ± SD, (n=3); *p<0.05 
considered significant compared with A53T α-Syn group by one-way ANOVA using a 















Figure 4.8 Post-treatment with 19-Ph-GA had little effect on A53T α-Syn induced 
proteasome inhibition. 5Y cells were transduced with adenovirus expressing mutant 
A53T α-Syn at an MOI 400 pfu/cell then treated with 19-Ph-GA (1 µM). After 48h cells 
were harvested and proteasome activities were determined by measuring cleavage of the 
fluorescent peptide Suc-Leu-Leu-Val-Tyr-AMC (chymotrypsin-like activity) at 380/460 
nm. These value are presented as mean ± SD, (n=4); *p < 0.05 is considered significant 
compared with control by ANOVA using Tukey’s multiple comparison test. 
19-Ph-GA significantly down regulated mTOR/p70S6K signaling in A53T α-Syn 
overexpressing cells 
MTOR (mTORC1)  regulates many signaling proteins involved in various cellular 
processes including cell growth, protein synthesis and autophagy (282). Since mTOR has 
been reported to be a client protein of Hsp90 (283), 19-Ph-GA might modulate mTOR 
activity in 5Y cells overexpressing A53T α-Syn. In contrast to a recent study (Jiang et al., 
2013), a sustained increase in the levels of LC3 II was observed after overexpression of 
either A53T or WT α-Syn in 5Y cells while the concomitant induction of p-mTOR and p-
p70S6K was only detected in A53T α-Syn overexpressing cells (Fig. 4.9 A, B and Fig. 
4.10). Increased expression of A53T α-Syn activated mTOR/p70S6K signaling in both a 
time and dose-dependent manner in 5Y cells (Fig. 4.9 C-D) suggesting a potential role of 
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mTOR/p70S6K signaling in A53T α-Syn induced toxicity. Importantly, 48h post-
treatment with 19-Ph-GA significantly attenuated the increases of p-mTOR and p-
p70S6K in A53T α-Syn overexpressing cells but had little effect on the amount of LC3 II 
(Fig. 4.11).  
 
Figure 4.9 MTOR/p70S6K signaling was activated by overexpression of A53T but not 
WT α-Syn. (A-B) Overexpression of A53T but not WT α-Syn for 72h significantly 
increased the levels of phosphorylated mTOR and p70S6K in 5Y cells. Increased amount 
of LC3 II was observed in both A53T and WT α-Syn overexpressing cells suggesting that 
autophagy was not directly mediated via the mTOR/p70S6K signaling. The white 
dividing line in the LC3 II blot indicates omission of three lanes on the gel from a 
separate time point and all lanes shown were from the same gel. (C) Overexpression of 
A53T α-Syn for 72h resulted in a dose-dependent increase in p-mTOR in 5Y cells. A 
sustained increase in p-p70S6K could also be detected until transduction with A53T α-
Syn at MOI 800 pfu/cell. The overexpression of either WT α-Syn or GFP adenoviral 
vector control did not have any significant effect on the levels of p-mTOR and p-
p70S6K. (D) A time-course study showed that transduction with A53T α- Syn at MOI 
400 pfu/cell increased the expression of p-mTOR and p-p70S6K in a time-dependent 
manner in 5Y cells. (B) Fold changes of LC3 II, p-mTOR and p-p70S6K levels in (A) are 
normalized to respective controls and estimated by densitometry. Values in (B) are 
presented as mean ± SD, (n=3); *p < 0.05, **p < 0.01, ***p < 0.001 are considered 




Figure 4.10 Increased expression of p-mTOR was observed in A53T but not WT α-Syn 
overexpressing cells. After transduction with adenovirus expressing A53T α-Syn or WT 
α-Syn at MOI 400 pfu/cell for 72h, 5Y cells were fixed and immunostained for α-Syn 
(red), p-mTOR (green) and nuclei (DAPI, blue) and then examined by confocal 
microscopy. Note the colocalization of p-mTOR and α-Syn (white arrow) suggesting an 






Figure 4.11 19-Ph-GA decreased mTOR activation that was associated with A53T α-Syn 
induced toxicity. (A-B) Post-treatment with 19-Ph-GA for 48h significantly blocked the 
activation of p-mTOR and p-p70S6K induced by A53T α-Syn. (B) Fold changes of LC3 
II, p-mTOR and p-p70S6K levels in (A) are normalized to respective controls and 
estimated by densitometry. Values in (B) are presented as mean ± SD, (n=3); *p<0.05, 
**p<0.01 is considered significant relative to control group; #p<0.05 is considered 
significant compared with A53T α-Syn group by one-way ANOVA using a Tukey’s 
multiple comparison test. 
Discussion 
Results in this study demonstrated that 19-Ph-GA, a novel BQA Hsp90 inhibitor 
induced significantly less toxicity relative to its parent quinone GA while still retaining 
the ability to induce HSPs in human dopaminergic 5Y cells. To evaluate the potential 
therapeutic effects of 19-Ph-GA in PD, an A53T α-Syn cell model was established using 
transient adenoviral transduction of human mutant A53T α-Syn in 5Y cells. The results 
demonstrated that 19-Ph-GA could effectively decrease the formation of high molecular 
mass α-Syn oligomers and toxicity of A53T α-Syn. 19-Ph-GA triggered a sustainable 
increase in expression of HSP and the temporal induction of autophagy both of which 
may play a role in the protective effects observed with 19-Ph-GA. Intriguingly, 
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mTOR/p70S6K signaling was activated by overexpression of A53T but not WT α-Syn 
and 19-Ph-GA could block mTOR activation. This effect may also contribute to the 
protective mechanism of 19-Ph-GA against A53T α-Syn induced toxicity but requires 
further investigation.  
The mechanisms of α-Syn degradation have not been fully elucidated, but protein 
handling systems have been shown to play a role in modulating the levels of intracellular 
α-Syn via multiple pathways: the 20/26S proteasome and/or autophagy mediates 
degradation of α-Syn to alleviate intracellular protein load (284, 285); and α-Syn could be 
chaperoned by HSPs including Hsp70 and Hsp27 to limit the formation of toxic 
oligomers (286-288). Interestingly, overexpression of α-Syn particularly its pathogenic 
form A53T α-Syn has been shown to impair functions of the UPS or CMA and lead to 
further accumulation of α-Syn (223). In this study, increased expression of A53T α-Syn 
was found to result in a significant loss of cell viability and that was associated with the 
formation of α-Syn oligomers as well as alterations in protein handling systems including 
decreased expression of Hsp27, Hsp70 and decreased proteasomal activity. 
Overexpression of WT α-Syn did not induce oligomer formation and toxicity in 5Y cells 
as observed with A53T α-Syn overexpression suggesting that formation of oligomers was 
important for triggering the toxicity of α-Syn.  
Inhibiting Hsp90 leads to compensatory induction of HSPs and has been proposed as 
an effective strategy for the therapy of neurodegenerative diseases (266, 289). In fact, 
because of their ability to induce Hsp70 several Hsp90 inhibitors have recently been 
tested in a rat α-Syn PD model (270, 290). However, the failure of these candidate 
molecules in ameliorating dopaminergic neurodegeneration indicated that the 
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compensatory upregulation of Hsp70 by itself may be insufficient to protect against α-
Syn toxicity (287, 291). The BQA class of Hsp90 inhibitors including GA and 17-AAG 
has been found to be effective in inducing both multiple HSPs and autophagy (269, 292, 
293). However, the protective effects of BQAs are accompanied by off-target toxicities 
limiting their use in neurodegenerative diseases. Therefore, the ability of novel 19-
substituted BQA analogs to alleviate toxicity induced by mutant α-Syn overexpression 
was examined. 19-substituted BQA analogs were synthesized to prevent direct 
conjugation with thiols at the 19 position (274) and studies have demonstrated that 19 
substitutions resulted in less toxicity when compared to their unsubstituted parent BQAs 
(273). Results in this study demonstrated that 19-Ph-GA was able to induce HSP 
expression and autophagy and exerted significant protective effects when tested in an 
A53T α-Syn cell model. After treatment with 19-Ph-GA, a significant reduction in HMW 
α-Syn oligomers as well as a redistribution of HMW α-Syn oligomers to smaller 
oligomers was observed. These effects on HMW α-Syn oligomers following treatment 
with 19-Ph-GA may be the result of induction of Hsp70, Hsp27 and/or autophagy. 
MTOR (TORC1) plays a key role in many cellular processes including cell growth, 
proliferation, metabolism and protein synthesis (294). Its activity can be monitored by 
following the phosphorylation of substrates such as p70S6K at Thr389 (295). The 
inhibition of mTOR typically results in induction of autophagy and has been proposed as 
an attractive strategy for the therapy of misfolded protein diseases (296). However, in 
some cases mTOR inhibition does not necessarily result in autophagy but instead 
autophagy may be positively regulated by mTOR (297) or may even be mTOR-
independent (298). The data demonstrated that overexpression of either A53T or WT α-
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Syn in 5Y cells could induce autophagy while the activation of mTOR was only detected 
in A53T α-Syn overexpressing cells. In addition, post-treatment with 19-Ph-GA for 48h 
significantly blocked the activation of mTOR/p70S6K signaling whereas it had no 
significant effect on LC3 II levels in A53T α-Syn overexpressing cells. These results 
suggest that mTOR activation is not necessary for synuclein induced autophagy. In fact, a 
number of previous studies have demonstrated that overexpression of pathogenic forms 
of α-Syn could activate compensatory autophagy in response to either impaired 
chaperone-mediated autophagy (CMA) or UPS activity (280, 299, 300). 
The activation of mTOR/p70S6K signaling may be important for A53T α-Syn 
induced toxicity in 5Y cells although the mechanisms remain unclear. It is possible that 
mTOR activated downstream p70S6K to upregulate protein synthesis including the 
synthesis of aberrant proteins such as A53T α-Syn and resulted in proteolytic stress and 
toxicity as previously reported in a cell model of Huntington’s disease (301). Recently, 
mTOR has also been found to drive the phosphorylation status of transcriptional factor 
EB (TFEB) preventing it from translocating to the nucleus and activating lysosome 
biogenesis (302). Since lysosomes are critical to the process of autophagy, 
overexpression of A53T α-Syn might activate mTOR to inhibit lysosome biogenesis and 
lead to incomplete autophagic degradation of α-Syn oligomers and toxicity in 5Y cells. 
Results in this study demonstrated that 19-Ph-GA was very effective in attenuating the 
increases of p-mTOR and p-p70S6K in A53T α-Syn overexpressing cells. It is possible 
that mTOR/p70S6K signaling may be overactivated under stress or disease conditions 
and since mTOR has been reported as an Hsp90 client protein (283), Hsp90 inhibitors 
like 19-Ph-GA may be particularly effective.  
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In summary, the data demonstrated that 19-Ph-GA an analog of GA showed 
decreased toxicity when compared to GA while maintaining the ability to induce a robust 
HSP response as well as modulating the activation of autophagy in 5Y cells. The multiple 
protective effects of 19-Ph-GA rendered 5Y cells more resistant to mutant A53T α-Syn 
induced adverse effects (Fig. 4.12). The data also provide proof of principle that 
compounds which stimulate the HSP response and autophagy such as 19-Ph-GA may be 
worthy of further translational studies for the therapy of protein folding diseases 
including PD.  
 
Figure 4.12 Protective effects of 19-Ph-GA on A53T α-Syn induced protein handling 
changes and toxicity in 5Y cells. Overexpression of A53T α-Syn (labeled in red) resulted 
in α-Syn oligomer formation and toxicity via perturbing major protein handling systems 
including increased proteasomal inhibition, ER stress response and decreased levels of 
HSPs. Autophagy could be activated by overexpression of either A53T or WT α-Syn 
(labeled in black) excluding the possibility that autophagic cell death was induced 
specifically by A53T α-Syn overexpression. MTOR/p70S6K signaling was not directed 
involved in A53T α-Syn induced autophagy but was positively related to the toxicity of 
A53T α-Syn. 19-Ph-GA (labeled in blue) activated Hsp70, Hsp27 and autophagy and 
ameliorated A53T α-Syn induced mTOR activation. Collectively, these mechanisms may 




SUMMARY AND FUTURE DIRECTIONS 
Naturally occurring quinones predominantly found in plants, fungi and bacteria have 
been used as dyes and drugs throughout history (3, 303). While quinones have many 
medicinal benefits, they also exist as toxic metabolites of xenobiotics including 
benzoquinone and naphthoquinone as well as endogenous biochemicals such as 
dopamine ortho-quinones (8, 243). Previous studies have attributed quinone induced 
toxicity to two major mechanisms: 1) formation of ROS and 2) arylation of 
macromolecular targets including tubulin, histone, topoisomerase II, and DNA (3, 10, 
304, 305). Although the mechanism of quinone toxicity has been extensively studied, the 
role of quinones in modulating protein handling systems has not been investigated in 
detail, particularly with respect to the interrelationship between quinone induced 
proteolytic stress and toxicity.  
In this thesis, three model quinones including the benzene metabolite BQ, the vitamin 
K and naphthoquinone analog MD and AC a highly reactive dopamine oxidation product 
were utilized to explore a potential novel route of quinone mediated toxicity involving 
modulation of cellular protein handling systems. Since quinones were hypothesized to 
target the 20S proteasome, the interconnectivity of proteasomal inhibition and 
compensatory responses in other protein handling systems was first characterized using 
the reversible proteasome inhibitor MG132 in rat dopaminergic N27 cells (Chapter II). 
The data suggest that the activation of major protein handling systems is a highly 
regulated process. The ER stress response was most rapidly triggered after proteasomal 
inhibition followed by autophagy and Hsp70 induction while the formation of 
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aggresomes was activated relatively late during the cell death phase. Additionally, 
autophagy was found to play a role in the clearance of ubiquitinated proteins during 
recovery of the cells from proteasomal inhibition. Overall, the results in Chapter II 
suggest that the mechanisms of induction of alternate protein handling systems and their 
temporal relationship may be important parameters determining the extent of 
accumulation of misfolded proteins in cells as a result of proteasomal inhibition.  
In Chapter III, the ability of quinones to inhibit the proteasome and modulate other 
protein handling systems was validated. The results demonstrated that AC could inhibit 
all three catalytic sites of the purified 20S proteasome, whereas BQ had a greater 
inhibition on the trypsin-like site, inhibited the chymotrypsin-like site to a lesser extent 
and had no effect on the caspase-like site. The fully substituted BQ analog DQ did not 
inhibit proteasomal activity suggesting a major role of arylation in BQ induced 
proteasomal inhibition. Although substituted analogs of AC were not synthetically 
accessible, earlier results by the Ross lab have demonstrated the inability of catalase 
and/or superoxide dismutase (SOD) to affect AC-induced proteasomal inhibition in rabbit 
reticulocyte lysate. These results suggest a major role of arylation in AC mediated 
proteasomal inhibition (12). It is likely that BQ and AC could modify the critical cysteine, 
lysine and glutamic acid residues on the catalytic subunits (β1, β2 and β5) or adjacent β 
subunits of the proteasome both of which may affect the activity of the peptidase sites as 
suggested by previous studies (50, 51, 57, 253, 306, 307). Therefore, a potential future 
area of research would be to focus on identification of the proteasome adducts of BQ and 
AC. The hypothesis that dopamine induced proteasomal inhibition was due to the 
formation of an AC-proteasome adduct could be tested and further verified by 
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identification of the AC-proteasome adduct. Both MALDI-TOF (matrix-assisted laser 
desorption ionization-time of flight) and LC-MS/MS analysis could potentially be 
utilized to identify the quinone-proteasome adduct as previously reported (306, 308). The 
major catalytic subunits of the 20S proteasome could also be separated and digested to 
small peptides (309-312) and used as in vitro reaction targets for quinones. The profile of 
quinone adducts on distinct subunits of the proteasome and the specific sites at which 
amino acids were modified by quinones could be identified. Currently, a BQ-albumin 
adduct is routinely used to monitor human exposure to benzene because it has a half-life 
of 13.5 days which is more stable than short-lived urinary metabolites in humans (313). 
Since the proteasome has a half-life of 12-15 days (314-316), identification of the BQ-
proteasome adduct in these studies might also provide insights into alternative 
biomarkers for monitoring human exposure to BQ and benzene.  
While arylation reactions are speculated to play a key role in proteasomal inhibition 
by quinones, overexpression of NQO1 did not result in significant differences in quinone 
induced proteasomal inhibition in N27 cells. It is possible that both arylation and redox 
cycling of quinones contribute to quinone-induced proteasomal inhibition in cells. In fact, 
previous studies have demonstrated that oxidative stress was able to impair proteasome 
function by direct oxidation of the 19S regulatory lid and β catalytic subunits of the 
proteasome (317-320).  
The results in Chapter III suggest that NQO1 could modulate the ER stress response 
to potentiate toxicity of AC and MD but protect against BQ toxicity. The data suggest 
that NQO1 mediated reduction to unstable hydroquinones and subsequent redox cycling 
may be important for the activation of the ER stress response and toxicity for both AC 
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and MD. These results also suggest that both arylation and redox cycling of quinones are 
critical for the activation of the ER stress response and toxicity. In addition to 
proteasomal inhibition, quinones may directly modify ER proteins such as ER protein 
disulfide isomerases to trigger the ER stress response. Therefore, a future study might 
focus on discriminating the role of arylation and oxidative stress in quinone induced ER 
stress response and its relationship to toxicity. Isogenic cell lines expressing either 
cytochrome P450 reductase or b5 reductase that increase one electron redox cycling of 
quinones will be generated. DQ and DMNQ, which can only redox cycle but are 
incapable of arylation could also be utilized in an attempt to define the relative roles of 
arylation and oxidative stress in quinone- induced ER stress response and toxicity.  
Because quinones were capable of inducing protein handling changes in cells, the 
ability of quinone-based 19BQA Hsp90 inhibitors to modulate protein handling systems 
was also examined in Chapter IV using human dopaminergic 5Y cells. The data 
demonstrated that 19BQAs in the GA series were more effective at inducing HSPs 
(Hsp70 and Hsp27) at relatively low doses (0.25-0.5 µM) compared with 19-substituted 
AAG and DMAG derivatives. The potential toxicity of all 19BQAs was examined using 
a short term MTT test as an initial screen. Overall, the data suggest that 19BQAs induce 
substantially decreased toxicity relative to their parent quinones GA, 17-AAG and 17-
DMAG in 5Y cells. While the relatively low toxicity of 19-Ph-GA a lead compound of 
19BQAs in the GA series has been confirmed using trypan blue exclusion and apoptosis 
assays, the toxicity of 19-substituted AAG and DMAG derivatives will also need to be 
validated by these methods.  
Additionally, the effect of 19-Ph-GA on protein handling was examined in Chapter 
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IV. The results demonstrated that treatment with relatively low doses (0.5-1 µM) of 19-
Ph-GA did not have any significant effects on proteasomal activity and the ER stress 
response but activated HSP expression and the turnover of autophagic flux in 5Y cells. 
Although at low doses 19-Me-GA and 19-Me-DMAG were less effective in HSP 
induction compared with 19-Ph-GA as well as their parent compounds GA and 17-
DMAG, they could induce robust HSP expression at relatively high doses (5-10 µM) and 
had little effect on prosurvival proteins. These results suggest that 19-Me-BQAs may also 
be worthy of further study.  
To better evaluate the potential protective effects of 19-Ph-GA on PD, an A53T α-
Syn overexpressing cell model was established. The results demonstrated that 19-Ph-GA 
could activate the HSP response and autophagy both of which may contribute to the 
decreased oligomer formation and toxicity of A53T α-Syn in 5Y cells. To further probe 
the action of 19-Ph-GA on the clearance of α-Syn oligomers, future studies might utilize 
RNA interference including siRNA against Atg5 and siRNA against HSF-1 to inhibit 
autophagy activation and HSP expression, respectively. Downregulation of Atg5 can 
disrupt the lipid conjugation of LC3 that in turn inhibits the conversion of LC3 I to LC3 
II and formation of autophagosomes. Since Hsp90 inhibitors including 19-Ph-GA induce 
HSP expression via activating HSF-1, downregulation of HSF-1 by siRNA will be an 
effective tool to inhibit the expression of a range of HSPs. Alternatively, downregulation 
of individual HSPs using siRNA against specific HSPs is another potential approach. 
Taken together, these experiments would assist in defining the relative roles of autophagy 
and HSPs in19-Ph-GA mediated protective effects in A53T α-Syn overexpressing cells. 
Taken together, these approaches will define the relative roles of autophagy and HSPs 
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in19-Ph-GA mediated protective effects on A53T α-Syn overexpressing cells.  
Dysregulation of the mTOR signaling pathway has been implicated in several 
neurodegenerative diseases including Alzheimer’s disease, PD, Huntington’s disease and 
epilepsy (282, 321). MTOR is activated through the PI3K/Akt pathway and can control 
neuronal protein synthesis via its downstream effectors p70S6K and eukaryotic initiation 
factor 4E-binding protein 1 (4EBP1). The results in Chapter IV have demonstrated that 
mTOR activation was only detected in A53T α-Syn but not WT α-Syn overexpressing 
cells. More importantly, 19-Ph-GA could significantly block the activation of mTOR in 
A53T α-Syn overexpressing cells. This effect may contribute to the protective 
mechanism of 19-Ph-GA against A53T α-Syn toxicity but requires further investigation. 
Future studies will need to define the role of mTOR in A53T α-Syn induced toxicity and 
two approaches could be used: 1) Define whether mTOR activates p70S6K to upregulate 
protein synthesis and leads to increased accumulation of A53T α-Syn and toxicity in 5Y 
cells as suggested by a recent study (301); 2) Characterize whether mTOR triggers the 
phosphorylation of TFEB and prevents it translocating to the nucleus and activating 
lysosome biogenesis. It is possible that overexpression of A53T α-Syn activates mTOR to 
compromise the degradation capacity of cells and leads to proteolytic stress and toxicity. 
Additionally, the question of whether A53T α-Syn induced autophagy is mTOR-
independent in 5Y cells could be addressed after downregulating mTOR expression by 
using siRNA approaches (298). 
The newly synthesized 19BQAs are a class of antitumor Hsp90 inhibitors that do not 
arylate cellular thiols compared with their parent drugs including GA, 17-AAG and 17-
DMAG, but they retain the ability to induce HSPs. The studies in Chapter IV focused on 
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19-Ph-GA have demonstrated proof of principle that compounds which stimulate the 
HSP response and autophagy may be worthy of further translational studies for the 
therapy of protein folding diseases including PD. The results suggest that 19-Ph-GA has 
diminished toxicity relative to GA, 17-AAG and 17-DMAG. In vivo pharmacokinetic 
and pharmacodynamic studies could be conducted to further evaluate the brain 
permeability and oral bioavailability of 19-Ph-GA. Several transgenic mouse and rat 
models overexpressing α-Syn have been developed previously. Although different 
promoters including the PDGF-β, murine Thy1, rat Th, mouse prion and hamster prion 
promoter were able to drive the A53T α-Syn transgene, the most pronounced behavioral 
alterations were only observed in the models with the highest expression levels of A53T 
α-Syn (322-324). Two recent studies have shown that the toxic oligomer formation and 
induction of the ER stress response were associated with α-synucleinopathy in A53T α-
Syn transgenic mouse models (325, 326). A future study might examine the potential 
protective effects of 19BQAs such as 19-Ph-GA on α-Syn oligomer formation and 
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APPENDIX A 
19BQAS IN THE 17-AAG AND 17-DMAG SERIES STUDIED IN CHAPTER IV 
 
Chemical structures of 19BQAs in the 17-AAG and 17-DMAG series. Substitutions at 
the 19-position (R) include methyl (Me), phenyl (Ph), 4-methoxy-phenyl (Ph-OMe), 4-




19-substituted AAG derivatives exhibited decreased toxicity and Hsp 70 induction 
activity relative to their parent quinone 17-AAG. (A) Growth inhibition induced by 19-
Me-AAG and 19-Ph-AAG in 5Y cells. Cells were treated with BQAs for 4hr then 
allowed to grow for an additional 72hr. Growth inhibition was measured using the MTT 
assay. (B) Immunblot analysis of biomarker of Hsp90 inhibition following treatment with 
BQAs at 1 µM for 16h. Note that 19-Me-AAG and 19-Ph-AAG did not induce effective 
Hsp70 expression compared with 17-AAG. 
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19-substituted DMAG exhibited decreased toxicity compared with their parent quinone 
17-DMAG. (A) Growth inhibition induced by 19BQAs in the 17-DMAG series in 5Y 
cells. Cells were treated with BQAs for 4hr then allowed to grow for an additional 72hr. 
Growth inhibition was measured using the MTT assay. (B-C) Immunblot analysis of 
biomarkers of Hsp90 inhibition following treatment with BQAs at the indicated 
concentration for 16h. Note that 19BQAs in the 17-DMAG series did not induce 




19-Me-BQAs at relatively high doses exerted comparable activity in HSP induction 
compared with their parent quinones GA, 17-AAG and 17-DMAG and had little effect on 
prosurvival proteins. Immunoblot analysis of biomarkers of Hsp90 inhibition following 
treatment with BQAs at relatively high doses for 16h. 
 
 
